Finex logo
Finex Intelligence

Market Signal Briefing

Wire-ready dashboard awaiting your first source connection.

Last news saved at Mar 30, 13:54 1mo ago Cron last ran Mar 30, 13:54 1mo ago Awaiting first source
Switch language
91,488 Stories ingested Auto-fetched market intel nonstop.
0 Distinct tickers Add sources to start tracking symbols
Trending sources Waiting for fresh intel
Hot tickers Surfacing from current coverage
Details Saved Published Title Source Tickers
2025-11-18 06:47 5mo ago
2025-11-18 01:00 5mo ago
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets stocknewsapi
ZYME
Strategy will combine internal innovation, licensing, and strategic acquisitions to drive sustainable value creation for shareholdersStrategic initiative follows positive topline results from pivotal Phase 3 HERIZON-GEA-01 trial evaluating zanidatamab in first-line gastroesophageal adenocarcinoma (GEA) and pasritamig advancing to registration studies by J&J Innovative Medicine (J&J)Eligible to receive up to $440.0 million in potential near-term milestone payments upon successful global regulatory approvals of Ziihera® in GEA Successful commercialization of Ziihera and execution of partnership strategy are expected to drive substantial royalty and milestone revenues with carefully managed R&D investmentsCompany authorizes a new share repurchase plan of $125.0 millionZymeworks to host a conference call with management today at 8:30 am Eastern Time (ET) VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced a novel strategic initiative focused on optimizing future cash flows from Ziihera® (zanidatamab-hrii), other licensed products and other healthcare assets. Together with the ability to leverage existing and future R&D partnerships and collaborations through internal innovation, this strategy seeks to optimize a long-term source of growing revenue streams with carefully managed R&D investments to establish a durable, profitable operating structure.

This strategic initiative is driven by an emerging licensed product portfolio with potential long-term and predictable cash flows, following yesterday’s announcement of positive topline data from the Phase 3 HERIZON-GEA-01 trial, taken together with pasritamig being advanced to Phase 3 registration studies by J&J.

For Ziihera, under the Company’s existing arrangements with Jazz and BeOne, Zymeworks has the potential to receive substantial near-term milestone payments related to future regulatory approvals in GEA totaling $440.0 million, as follows: USA - $250.0 million; EU - $100.0 million; Japan - $75.0 million; China - $15.0 million. The Company also expects that royalty revenue from Ziihera sales will increase as potential regulatory approvals are obtained in global markets for GEA. In addition, Zymeworks could be eligible to receive future milestones and increased royalties from the development, regulatory approval, and commercialization of any additional indications for Ziihera by Jazz and BeOne, including breast cancer.

For pasritamig, under the Company’s existing arrangements with J&J, Zymeworks remains eligible for up to $434.0 million in additional milestone payments for continued development, regulatory approval and commercialization of pasritamig by J&J as well as a mid-single digit royalty on pasritamig sales.

Differentiated Strategy Integrating a Royalty-Driven Growth Operation with a Productive In-house R&D Organization

“With Ziihera as our foundational licensed product, we have made the strategic decision to evolve from a traditional biotechnology company into a royalty-driven organization differentiated by in-house R&D capabilities,” said Kenneth Galbraith, Chair and Chief Executive Officer. “By having the capability to reinvest expected proceeds from the development and commercialization of Ziihera, pasritamig, and potentially other products, we aim for continued growth in value of our royalty portfolio while continuing to invest in R&D focused on internal and acquired product candidates as a source of future innovation and partnerships.”

The Company’s Board of Directors and management conducted a thorough strategic review with independent financial and legal advisors to determine the optimal path for long-term value creation, given the significant future cash flows anticipated from Ziihera, pasritamig, and other licensed products and product candidates. Zymeworks believes that this integrated approach allows for thoughtful capital allocation to deliver long-term and meaningful returns for shareholders. The Company anticipates providing these returns to shareholders in a tax-efficient manner through a mixture of (1) compounding existing royalty streams by thoughtfully re-investing proceeds from licensed products in other assets that do not have a traditional biotechnology risk profile and (2) returning excess capital directly to shareholders via share repurchase programs or special dividends.

Mr. Galbraith added, “We are embarking on this novel strategic initiative at a time when there are substantial opportunities in the healthcare sector to acquire, protect, and grow cash flow streams from existing partnerships, and to consider forming additional partnerships and collaborations whether originating from our wholly-owned product candidates and technology platforms, or accessed externally. We intend to fund our healthcare asset aggregation strategy through a combination of cash flows arising from current licensed assets along with the potential for external funding where it can be secured at a reasonable cost of capital. We believe that our differentiated strategy for accessing and carefully managing licensed products and other healthcare assets, coupled with the infrastructure we have developed to identify, evaluate and secure such assets, will enable us to generate attractive returns on invested capital, while supporting the early-stage development of innovative medicines.”

Mr. Galbraith concluded, “We believe our recent governance and leadership enhancements, such as the appointment of Scott Platshon as Acting Chief Investment Officer today, will further strengthen the Company’s ability to accelerate execution of this strategic initiative. These strategic appointments bring additional expertise that we expect will complement our existing scientific, clinical, and business leadership and build a stronger foundation to drive our growth strategy towards long-term value creation.”

Integration of Partnerships & Collaborations into Our R&D Operations

Zymeworks’ R&D operations will continue advancing its pipeline of innovative multifunctional therapeutics and utilizing our technology platforms, which represent potential opportunities to form new partnerships and collaborations, while preserving the legacy and impact of Zymeworks’ scientific platforms. The Company expects future partnerships and collaborations to play an important role in funding ongoing R&D investments, reducing reliance on our internal capital and preserving the long-term value of its existing scientific programs. The Company believes this continued discipline in capital allocation to R&D investments and financial contributions from existing and new potential partnerships, coupled with risk-sharing for late-stage development, will help reduce the need to use future milestone and royalty payments from our portfolio to fund planned R&D operations.

Share Repurchase Plan Authorization

From August 2024 to date, the Company has used $60.0 million in available cash resources to repurchase and retire approximately 4.4 million shares of common stock, representing approximately 6% of the Company’s current issued and outstanding shares. These share repurchases have been primarily funded from Ziihera development milestones related to initial regulatory approvals in biliary tract cancer in both the USA and China and cumulative royalties received from Ziihera sales to date by Jazz and BeOne.

In order to have the flexibility to opportunistically allocate excess capital to share repurchases, today the Company announced that its Board of Directors has authorized a new share repurchase plan under which the Company may repurchase up to $125.0 million of the Company’s outstanding common stock.

Financial Position

As of September 30, 2025, Zymeworks reported cash, cash equivalents and investments of $299.4 million. Over the past twelve months, the Company implemented adjustments to R&D operations, including pausing clinical development of ZW220 and ZW171, and completed certain headcount and other cost reductions to help streamline our future operating cost structure. The Company expects continued discipline in operations and capital allocation, as well as financial contributions from new potential partnerships and collaborations to provide a long-term source of external capital to help fund ongoing R&D investments.

Assuming the full execution of the $125.0 million share repurchase plan, we currently expect our existing cash resources of $299.4 million, as of September 30, 2025, when combined with the inclusion of anticipated milestone payments associated with potential approvals of Ziihera in GEA in the United States, Europe, Japan, and China, will enable us to fund planned operations beyond 2028. This anticipated cash runway does not take into account any contribution from additional future milestone payments or royalties related to Ziihera, other current licensed product candidates or contributions from future partnerships and collaborations.

Investor & Analyst Call

A live webcast will be held today at 8:30 am ET to discuss the Company’s growth strategy and to answer questions. Dial-in details and webcast replay will be available on Zymeworks’ website at https://ir.zymeworks.com/events-and-presentations.

Additional Information Regarding the Share Repurchase Program

Under the Company’s new share repurchase program announced today, shares of common stock may be repurchased opportunistically in open market transactions, or other means in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (Exchange Act), and Rule 10b-18 of the Exchange Act. The timing, number of shares repurchased, and prices paid for the shares under this repurchase plan will depend on general business and market conditions as well as corporate and regulatory limitations, prevailing stock prices, and other considerations. The share repurchase plan may be suspended or discontinued at any time and does not obligate the Company to acquire any amount of common stock.

About Zymeworks Inc.

Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. The Company’s asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera® (zanidatamab-hrii) and other licensed products and product candidates such as pasritamig. In addition, Zymeworks is also building a portfolio of healthcare assets that can generate strong cash flows, while supporting the early-stage development of innovative medicines. Zymeworks engineered and developed Ziihera® (zanidatamab-hrii), a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology and has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zymeworks is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.

Cautionary Note Regarding Forward-Looking Statements
This press release includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to Zymeworks’ expectations regarding implementation of its strategic priorities and the anticipated benefits thereof, including shareholder returns and the anticipated manner of such returns; anticipated optimality of strategic initiatives; implementation of its evolving asset aggregation strategy, including existing and potential future royalty streams and existing and potential new partnerships; the anticipated benefits of its collaboration agreements, including Zymeworks’ ability to receive any future milestone payments and royalties thereunder; statements relating to potential milestone payments upon regulatory approvals of Ziihera in GEA and the timing thereof; statements that relate to the expected contributions of personnel to Zymeworks’ strategic goals; statements that relate to Zymeworks’ ability to execute the share repurchase plan, in whole or in part; expected timing and amount of repurchases; Zymeworks’ ability to pursue its business objectives following repurchases under the share repurchase plan; anticipated capital allocation strategy; industry opportunities for acquisition of new revenue streams or collaborations; the potential addressable market of zanidatamab; the timing of and results of interactions with regulators; Zymeworks’ clinical development of its product candidates and enrollment in its clinical trials; the timing and status of ongoing and future studies and the related data; anticipated preclinical and clinical data presentations; expectations regarding future regulatory filings and approvals and the timing thereof; potential safety profile and therapeutic effects of zanidatamab and Zymeworks’ other product candidates; expected financial performance and future financial position; the commercial potential of technology platforms and product candidates; Zymeworks’ ability to satisfy potential regulatory and commercial milestones with existing and future partners; the timing and status of ongoing and future studies and the release of data; anticipated continued receipt of revenue from existing and future partners; Zymeworks’ early-stage pipeline; anticipated sufficiency of existing cash resources, when assuming full execution of the share repurchase plan and combined with the assumed receipt of certain anticipated regulatory milestones, to fund Zymeworks’ planned operations beyond 2028; Zymeworks’ ability to execute new collaborations and partnerships and other information that is not historical information. When used herein, words such as “plan”, “believe”, “expect”, “may”, “continue”, “anticipate”, “potential”, “will”, “on track”, “progress”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: any of Zymeworks’ or its partners’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; Zymeworks may not be able to execute the share repurchase plan, in whole or in part; the anticipated benefits of the share repurchase plan may not be realized; Zymeworks may not achieve milestones or receive additional payments under its collaborations; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions, including the impact of tariffs; potential negative impacts of FDA regulatory delays and uncertainty around recent policy developments, changes in the leadership of federal agencies such as the FDA, staff layoffs, budget cuts to agency programs and research, and changes in drug pricing controls; the impact of pandemics and other health crises on Zymeworks’ business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks’ behalf; zanidatamab may not be successfully commercialized; Zymeworks’ evolution of its business strategy related to anticipated and potential future milestones and royalty streams and existing and potential new partnerships may not be successfully implemented; Zymeworks’ evolution of its business strategy may not deliver meaningful shareholder returns; Zymeworks may be unsuccessful in actively managing and/or aggregating revenue-generating assets alongside its active R&D operations; ongoing and future clinical trials may not demonstrate safety and efficacy of any of Zymeworks’ or its collaborators’ product candidates; Zymeworks’ assumptions and estimates regarding its financial condition, future financial performance and estimated cash runway may be incorrect; inability to maintain or enter into new partnerships or strategic collaborations; and the factors described under “Risk Factors” in Zymeworks’ quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at www.sec.gov and www.sedarplus.ca).

Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.

Contacts:

Investor Inquiries:
Shrinal Inamdar
Senior Director, Investor Relations
(604) 678-1388
[email protected]

Media Inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
[email protected]
2025-11-18 06:47 5mo ago
2025-11-18 01:00 5mo ago
AkzoNobel and Axalta to Combine in All-Stock Merger of Equals, Creating a Premier Global Coatings Company stocknewsapi
AXTA
Creates a global coatings leader with $17 billion in revenue and an enterprise value of $25 billionSignificant value creation with approximately $600 million in cost synergies supporting strategic and capital allocation priorities Combines highly complementary portfolios across end markets, driving stronger revenue growth, enhanced profitability and increased value for customers Expands geographic reach, brings together world-class technology and innovation platforms and offers a full spectrum of solutions to deliver exceptional value to customers Highly attractive financial profile featuring strong EBITDA margins and robust cash flow generationOne‑tier Board to be led by current Axalta Chair Rakesh Sachdev as Chair; AkzoNobel CEO Greg Poux-Guillaume to serve as CEO of the combined companyCombined company to transition to a single NYSE listing; dual headquarters in Amsterdam and Philadelphia and domiciled in the NetherlandsCompanies to host joint investor conference call November 18 at 8:30 a.m. EST / 2:30 p.m. CET AMSTERDAM and PHILADELPHIA, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Akzo Nobel N.V. (AKZA; AKZOY) (“AkzoNobel”) and Axalta Coating Systems Ltd. (NYSE:AXTA) (“Axalta”) today announced that they have entered into a definitive agreement to combine in an all-stock merger of equals, creating a premier global coatings company with an enterprise value of approximately $25 billion.

The combination brings together two coatings industry leaders with complementary portfolios of highly regarded brands to better serve customers across key end markets and enhance value for shareholders, employees and other stakeholders. Anchored in both companies’ proud histories and broad expertise, the combined business will have a highly attractive financial profile, industry-leading innovation capabilities and a balanced global footprint spanning over 160 countries to bring global capabilities to local customers. 

With attractive margins and robust cash flow generation, the combined company will be well positioned to drive substantial growth and shareholder value creation, building on 2024 revenues of approximately $17 billion and $1.5 billion in pro forma Adjusted Free Cash Flow.1,2,3 The combination is expected to drive identified and actionable run-rate synergies of approximately $600 million, 90% of which are expected to be achieved within the first three years following the close of the transaction.

Greg Poux-Guillaume, Chief Executive Officer and Chairman of the Board of Management of AkzoNobel, said, “We’re excited to enter a new chapter in our long and proud history as a leader in the paints and coatings industry. This merger will allow us to accelerate our growth ambitions by bringing together highly complementary technologies, expertise and passionate people to unlock our full combined potential. I am excited to lead our talented teams in bringing the best of both companies to our customers and shareholders, delivering outstanding value to both.”

Ben Noteboom, Chairman of the Supervisory Board of AkzoNobel, stated, “This combination represents a compelling opportunity. It’s a great value proposition for all our stakeholders both in the Netherlands, where we maintain our domicile and internationally, including our shareholders, customers and employees. It will create a world leader in coatings and is a significant step that will drive sustainable growth and allow us to better serve our customers. By uniting two world-class organizations, we’re creating a strong platform for the future, built on a solid foundation of shared values and heritage.”

Chris Villavarayan, CEO and President of Axalta, stated, “We are pleased to enter into this transaction with AkzoNobel and join our best-in-class platforms to enhance innovation, develop new capabilities and further strengthen customer relationships. As our industry continues to grow and evolve, this combination with AkzoNobel enables us to do the same, with a sharper competitive edge and new avenues and opportunities for growth. Together, AkzoNobel and Axalta are positioned to establish a profitable and sustainable path forward as a leader in the coatings industry. Like AkzoNobel, we value our people as our greatest asset, and we are excited to unite our rich, innovation-focused cultures.”

Rakesh Sachdev, Chair of the Axalta Board of Directors, stated, “The Axalta Board is confident that this combination with AkzoNobel will create significant value for our shareholders as we move ahead. Led by an experienced management team with a track record of operational efficiency and excellence, we expect the meaningful synergy opportunities and enhanced financial profile of the combined company will drive substantial value creation. We look forward to joining Axalta’s and AkzoNobel’s strengths to create new opportunities across our global stakeholder base.”

Compelling Strategic and Financial Benefits of the Transaction

Diversified and balanced portfolio of leading brands. The merger brings together AkzoNobel’s and Axalta’s complementary portfolios to create a full spectrum offering of coatings solutions, with first-rate franchises across Powder, Aerospace, Refinish, Mobility, Marine & Protective, Industrial Coatings and Decorative Paints. The combined portfolio will be differentiated by its breadth of solutions across approximately 100 well-known brands.Increased geographic scale and enhanced commercial reach. The combined company will have an enhanced global footprint spanning 173 manufacturing sites and 91 R&D facilities worldwide, enabling it to bring global capabilities to local customers. Through increased local presence in key geographies, AkzoNobel and Axalta customers are expected to benefit from deep channel access to coatings and product support, further strengthening customer relationships.Enhanced capabilities to deliver customer-centric innovation. The combination will enable AkzoNobel and Axalta to deliver increasingly advanced and differentiated products by combining existing technological capabilities across end markets. Joining Axalta’s Refinish, Light Vehicle and Commercial and Industrial Coatings businesses with AkzoNobel’s Powder Coatings, Refinish, Aerospace Coatings, Marine & Protective, Industrial Coatings and Decorative Paints businesses will create an innovative platform to deliver exceptional value to customers. In addition, sharing best practices across two leading research platforms in the coatings space, is expected to accelerate high-value innovation. The combined company will have approximately $400 million combined annual R&D spend, 91 global R&D centers for local customer needs, approximately 4,200 research fellows, scientists and engineers, and approximately 3,200 granted and pending patent applications.Substantial synergy opportunities driving value creation. The combination is expected to generate pre-tax run-rate synergies of approximately $600 million, with 90% of synergies expected to be achieved within the first three years following the close of the transaction. The targeted synergies are identified and actionable, arising primarily from procurement, SG&A efficiencies, footprint optimization and improved supply chain management.Highly attractive financial profile with strong margins and substantial cash flow generation. Inclusive of run-rate synergies, the combined company is expected to have industry-leading profitability with strong Adjusted EBITDA margins approaching 20% and substantial cash flow generation. Revenues are expected to be approximately $17 billion, with Adjusted EBITDA of $3.3 billion and pro forma Adjusted Free Cash Flow of $1.5 billion. This will provide significant flexibility to support strategic and capital allocation priorities, including consistent capital returns through a regular dividend. Net leverage is targeted to be 2.0x to 2.5x, with a strong commitment to holding an investment grade credit rating.  Leadership, Corporate Governance and Headquarters

Upon closing, the combined company will have a one-tier Board, led by Rakesh Sachdev, current Chair of the Axalta Board of Directors. Ben Noteboom, current Chairman of the AkzoNobel Supervisory Board, will serve as Vice Chair. The Board will be composed of 11 directors – four from each company and three independent members. Of the 11 Board members, two will be executive directors and nine will be non-executive directors. Each company expects to hold its respective Extraordinary General Meeting of Shareholders tentatively in mid-2026.

Current AkzoNobel CEO, Greg Poux-Guillaume, will serve as CEO of the combined company, and current Axalta CEO, Chris Villavarayan, will serve as Deputy CEO. Current Axalta SVP and CFO, Carl Anderson, will serve as the CFO of the combined company. Current AkzoNobel CFO, Maarten de Vries, will retire from AkzoNobel prior to closing as previously announced.

The combined company will assume a new name and ticker symbol, which will be announced in due course, and will have dual headquarters in Amsterdam and Philadelphia. It will be organized under a Dutch holding company with tax residency in the Netherlands. Following a period of dual listing on Euronext Amsterdam and the New York Stock Exchange (“NYSE”), shares of the combined company’s common stock will be listed solely on NYSE.

Transaction Details

Under the terms of the agreement, which has been unanimously approved by the AkzoNobel Supervisory Board, the AkzoNobel Board of Management and the Axalta Board of Directors, Axalta shareholders will receive 0.6539 shares of AkzoNobel stock for each share of Axalta common stock owned.

In connection with the transaction, AkzoNobel will pay a special cash dividend to AkzoNobel shareholders equal to €2.5 billion minus the aggregate amount of any regular annual and interim dividends paid by AkzoNobel to AkzoNobel shareholders in 2026 prior to completion. AkzoNobel shareholders will own 55% and Axalta shareholders will own 45% of the combined company on a pro forma basis immediately after closing.

The companies expect the transaction to close in late 2026 to early 2027, subject to approval by shareholders of both AkzoNobel and Axalta, the receipt of requisite regulatory approvals, authorization for the combined company’s shares to be listed on NYSE, payment of the special dividend by AkzoNobel, completion of AkzoNobel’s works council consultation requirements and the satisfaction of other customary closing conditions.

Dividends and Share Buybacks Between Signing and Close

In light of the announced transaction, both AkzoNobel and Axalta have agreed to suspend any ongoing or announced share buyback programs, effective immediately.

AkzoNobel intends to continue paying regular ordinary dividends in line with its existing dividend policy through closing, subject to customary approvals and applicable legal requirements. No extraordinary or additional distributions are expected from either company prior to completion, other than AkzoNobel’s special dividend pursuant to the transaction terms.

Advisors

Morgan Stanley & Co International plc is serving as sole financial advisor, De Brauw Blackstone Westbroek N.V. and Davis Polk are serving as legal counsel, and FGS Global is serving as strategic communications advisor to AkzoNobel. In addition, Lazard B.V. and Wakkie+Perrick are acting as financial and legal advisors, respectively, to the Supervisory Board from AkzoNobel.

Evercore and J.P. Morgan Securities LLC are acting as co-lead financial advisors to Axalta. Incentrum Group is also providing financial advice. Additionally, Cravath, Swaine & Moore LLP and NautaDutilh N.V. are serving as legal counsel, and Joele Frank, Wilkinson Brimmer Katcher is serving as strategic communications advisor to Axalta.

Conference Call and Additional Materials

AkzoNobel and Axalta will host a joint investor conference call today at 8:30 a.m. EST / 2:30 p.m. CET to discuss the transaction.

The conference call will be available via live webcast on the investor relations section of each company’s website at https://www.akzonobel.com/en/investors/events and https://ir.axalta.com, or directly at the following web address: https://event.choruscall.com/mediaframe/webcast.html?webcastid=V5nvvQdI. Associated presentation materials will also be available for viewing on the respective websites prior to the call.

The conference call can also be accessed by dialing +1 (877) 407-4177 within the U.S. International numbers can access the conference call by dialing +1 (201) 689-8325 or by clicking here. An archive of the webcast will be available for one week.

About AkzoNobel

Since 1792, we’ve been supplying the innovative paints and coatings that help to color people’s lives and protect what matters most. Our world class portfolio of brands – including Dulux, International, Sikkens and Interpon – is trusted by customers around the globe. We’re active in more than 150 countries and use our expertise to sustain and enhance everyday life. Because we believe every surface is an opportunity. It’s what you’d expect from a pioneering and long-established paints company that’s dedicated to providing more sustainable solutions and preserving the best of what we have today – while creating an even better tomorrow. Let’s paint the future together.

About Axalta Coating Systems

Axalta is a global leader in the coatings industry, providing customers with innovative, colorful, beautiful and sustainable coatings solutions. From light vehicles, commercial vehicles and refinish applications to electric motors, building facades and other industrial applications, our coatings are designed to prevent corrosion, increase productivity and enhance durability. With more than 150 years of experience in the coatings industry, the global team at Axalta continues to find ways to serve our more than 100,000 customers in over 140 countries better every day with the finest coatings, application systems and technology. For more information visit axalta.com and follow us @axalta on X.

Important Information
This is a joint press release by AkzoNobel and Axalta. This joint press release is issued pursuant to the provisions of Section 17, paragraph 1 of the European Market Abuse Regulation (596/2014) in connection with the intended recommended combination, via a merger of equals, of the businesses of AkzoNobel and Axalta.

General restrictions
This communication is not for release, publication, or distribution, in whole or in part, in or into, directly or indirectly, any jurisdiction in which such release, publication, or distribution would be unlawful.

This communication is not a prospectus and the information in this communication is not intended to be complete. This communication is for informational purposes only and is not intended to be and shall not constitute a solicitation of any vote or approval, or an offer to buy or sell, or the solicitation of an offer to buy or sell, any securities, or an invitation or recommendation to subscribe for, acquire or buy securities of AkzoNobel or Axalta or any other financial products or securities, in any place or jurisdiction, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended (the “Securities Act”).

Any decision to purchase, subscribe for, otherwise acquire, sell or otherwise dispose of any securities must be made only on the basis of the information contained in and incorporated by reference into the prospectus with respect to the shares to be allotted by AkzoNobel in the proposed transaction once published. A prospectus in relation to the proposed transaction described in this communication is expected to be published in due course.

The distribution of this communication may, in some countries, be restricted by law or regulation. Accordingly, persons who come into possession of this document should inform themselves of and observe these restrictions. To the fullest extent permitted by applicable law, AkzoNobel and Axalta disclaim any responsibility or liability for the violation of any such restrictions by any person. Neither AkzoNobel, nor Axalta, nor any of their advisors assume any responsibility for any violation by any person of any of these restrictions. Shareholders of AkzoNobel and Axalta, respectively, with any doubt as to their position should consult an appropriate professional advisor without delay.

This communication is addressed to and directed only at, persons who are outside the United Kingdom or, in the United Kingdom, at persons who are: (i) persons having professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), (ii) persons falling within Article 49(2)(a) to (d) of the Order, or (iii) persons to whom it may otherwise lawfully be communicated pursuant to the Order (all such persons together being referred to as, “Relevant Persons”). This communication is directed only at Relevant Persons. Other persons should not act or rely on this communication or any of its contents. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with such persons. Solicitations resulting from this communication will only be responded to if the person concerned is a Relevant Person.

Additional Information and Where to Find It
In connection with the proposed transaction between AkzoNobel and Axalta, AkzoNobel will file with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form F-4, which will include a proxy statement of Axalta that also constitutes a prospectus with respect to the shares to be offered by AkzoNobel in the proposed transaction. The definitive proxy statement/prospectus will be sent to the shareholders of Axalta. Each of AkzoNobel and Axalta will also file other relevant documents in connection with the proposed transaction. This communication is not a substitute for any registration statement, proxy statement/prospectus or other documents AkzoNobel and/or Axalta may file with the SEC or any other competent regulator in connection with the proposed transaction. This communication does not contain all the information that should be considered concerning the proposed transaction and is not intended to form the basis of any investment decision or any other decision in respect of the proposed transaction. BEFORE MAKING ANY VOTING OR INVESTMENT DECISIONS, INVESTORS, STOCKHOLDERS AND SHAREHOLDERS OF AKZONOBEL AND AXALTA ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE PROXY STATEMENT/PROSPECTUS, AS APPLICABLE, AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, IN CONNECTION WITH THE PROPOSED TRANSACTION WHEN THEY BECOME AVAILABLE, AS THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT AKZONOBEL, AXALTA, THE PROPOSED TRANSACTION AND RELATED MATTERS. The registration statement and proxy statement/prospectus and other relevant documents filed by AkzoNobel and Axalta with the SEC, when filed, will be available free of charge at the SEC’s website at www.sec.gov. In addition, investors and shareholders will be able to obtain free copies of the proxy statement/prospectus and other documents filed with the SEC from Axalta’s investor relations webpage at https://ir.axalta.com/sec-filings/all-sec-filings or from AkzoNobel’s investor relations webpage at https://www.akzonobel.com/en/investors.

The contents of this communication should not be construed as financial, legal, business, investment, tax or other professional advice. Each recipient should consult with its own professional advisors for any such matter and advice.

Participants in the Solicitation
This communication is not a solicitation of proxies in connection with the proposed transaction. However, under SEC rules, AkzoNobel, Axalta and certain of their respective directors and executive officers and other members of their respective management and employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of proxies in connection with the proposed transaction, including a description of their direct or indirect interests in the proposed transaction, by security holdings or otherwise, will be set forth in the proxy statement/prospectus and other relevant materials when it is filed with the SEC. Information regarding the directors and executive officers of Axalta is contained in Axalta’s proxy statement for its 2025 annual meeting of stockholders, filed with the SEC April 22, 2025, its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was filed with the SEC on February 13, 2025, subsequent statements of beneficial ownership on file with the SEC, including the Initial Statements of Beneficial Ownership on Form 3, Statements of Change in Ownership on Form 4 or Annual Statements of Beneficial Ownership on Form 5 filed with the SEC on: 2/19/2025, 2/19/25, 2/19/2025, 2/19/25, 2/19/2025, 3/4/2025, 3/4/2025, 3/4/2025, 3/4/2025, 3/4/2025, 3/4/2025, 3/4/2025, 3/4/2025, 3/4/2025, 3/4/2025, 3/4/2025, 3/4/2025, 3/4/2025, 3/4/2025, 3/6/2025, 3/6/2025, 3/6/2025, 3/6/2025, 3/6/2025, 3/6/2025, 3/6/2025, 3/6/2025, 3/6/2025, 3/6/2025, 3/6/2025, 3/6/2025, 3/6/2025, 3/6/2025, 3/6/2025, 3/6/2025, 8/5/2025, 8/18/2025, 8/21/2025, 9/23/2025 and 9/23/2025, and other filings made from time to time with the SEC. Information about AkzoNobel’s supervisory board members and members of the board of management is set forth in AkzoNobel’s latest annual report, as filed with the AFM, the Dutch trader register and on its website at https://www.akzonobel.com/en/investors/results-center, and as updated from time to time via filings made by AkzoNobel with the AFM. Additional information regarding the interests of persons who may, under the rules of the SEC, be deemed participants in the solicitation of Axalta security holders in connection with the proposed transaction, which may, in some cases, be different than those of Axalta’s shareholders generally, including a description of their direct or indirect interests, by security holdings or otherwise, will be set forth in the proxy statement/prospectus and other relevant materials when they are filed with the SEC. These documents can be obtained free of charge from the sources indicated above.

Market data
Information provided herein as it relates to the market environment in which each of AkzoNobel and Axalta operate or any market developments or trends is based on data and reports prepared by third parties and/or AkzoNobel or Axalta based on internal information and information derived from such third-party sources. Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data.

Cautionary Statement Concerning Forward-Looking Statements
This communication contains forward-looking statements as that term is defined in Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995, regarding, among other things, statements about management’s expectations of AkzoNobel’s and Axalta’s future operating and financial performance, product development, market position, and business strategy. Such forward-looking statements can sometimes be identified by the use of forward-looking terms such as “believes,” “expects,” “may,” “will,” “shall,” “should,” “would,” “could,” “potential,” “seeks,” “aims,” “projects,” “predicts,” “is optimistic,” “is confident,” “intends,” “plans,” “estimates,” “targets,” “anticipates,” “continues” or other comparable terms or negatives of these terms, but not all forward-looking statements include such identifying words. You are cautioned not to rely on these forward-looking statements. Forward-looking statements are based upon current plans, estimates and expectations that are subject to risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. We can give no assurance that such plans, estimates or expectations will be achieved and therefore, actual results may differ materially from any plans, estimates or expectations in such forward-looking statements. Important factors that could cause actual results to differ materially from such plans, estimates or expectations include: a condition to the closing of the proposed transaction may not be satisfied; the occurrence of any event that can give rise to termination of the proposed transaction; a regulatory approval that may be required for the proposed transaction is delayed, is not obtained or is obtained subject to conditions that are not anticipated; AkzoNobel and Axalta are unable to achieve the synergies and value creation contemplated by the proposed transaction; AkzoNobel and Axalta are unable to promptly and effectively integrate their businesses; management’s time and attention is diverted on transaction related issues; the possibility that competing offers or acquisition proposals may be made; disruption from the proposed transaction makes it more difficult to maintain business, contractual and operational relationships; the credit ratings of AkzoNobel or Axalta decline following the proposed transaction; legal proceedings are instituted against AkzoNobel or Axalta, including resulting expense or delay; AkzoNobel or Axalta is unable to retain or hire key personnel; the communication or the consummation of the proposed acquisition has a negative effect on the market price of the capital stock of AkzoNobel or Axalta or on AkzoNobel’s or Axalta’s operating results; evolving legal, regulatory and tax regimes; changes in economic, financial, political and regulatory conditions, in the Netherlands, the United States and elsewhere, and other factors that contribute to uncertainty and volatility, natural and man-made disasters, civil unrest, pandemics (e.g., the coronavirus (COVID-19) pandemic), geopolitical uncertainty, and conditions that may result from legislative, regulatory, trade and policy changes associated with the current or subsequent United States or Netherlands administration; the ability of AkzoNobel or Axalta to successfully recover from a disaster or other business continuity problem due to a hurricane, flood, earthquake, terrorist attack, war, pandemic, security breach, cyber-attack, power loss, telecommunications failure or other natural or man-made event, including the ability to function remotely during long-term disruptions; the impact of public health crises, such as pandemics and epidemics and any related company or governmental policies and actions to protect the health and safety of individuals or governmental policies or actions to maintain the functioning of national or global economies and markets, including any quarantine, “shelter in place,” “stay at home,” workforce reduction, social distancing, shut down or similar actions and policies; actions by third parties, including government agencies; the risk that disruptions from the proposed transaction will harm AkzoNobel’s or Axalta’s business, including current plans and operations and/or divert management’s attention from AkzoNobel’s or Axalta’s ongoing business operations; certain restrictions during the pendency of the acquisition that may impact AkzoNobel’s or Axalta’s ability to pursue certain business opportunities or strategic transactions; AkzoNobel’s or Axalta’s ability to meet expectations regarding the accounting and tax treatments of the proposed transaction; the risks and uncertainties discussed in AkzoNobel’s latest annual report as filed with the AFM, the Dutch trader register and on its website at https://www.akzonobel.com/en/investors/results-center; and the risks and uncertainties discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections in Axalta’s reports filed with the SEC. These risks, as well as other risks associated with the proposed transaction, will be more fully discussed in the proxy statement/prospectus. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. We caution you not to place undue reliance on any of these forward-looking statements as they are not guarantees of future performance or outcomes and that actual performance and outcomes, including, without limitation, our actual results of operations, financial condition and liquidity, and the development of new markets or market segments in which we operate, may differ materially from those made in or suggested by the forward-looking statements contained in this communication. Except as required by law, neither AkzoNobel nor Axalta assumes any obligation to update or revise the information contained herein, which speaks only as of the date hereof.

Non-GAAP and Non-IFRS Financial Measures
This communication contains certain non-GAAP financial measures and/or non-IFRS financial measures that AkzoNobel and Axalta believe are helpful in understanding the anticipated strategic and financial benefits of the proposed transaction. AkzoNobel's and Axalta's management regularly use a variety of financial measures that are not in accordance with GAAP or IFRS for forecasting, budgeting and measuring financial performance. The non-GAAP financial measures and/or non-IFRS financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP or IFRS measures. While AkzoNobel and Axalta believe that these non-GAAP financial measures and/or non-IFRS financial measures provide meaningful information to help shareholders understand the anticipated strategic and financial benefits of the proposed transaction, there are limitations associated with the use of these non-GAAP financial measures and/or non-IFRS financial measures. These non-GAAP financial measures and/or non-IFRS financial measures are not prepared in accordance with GAAP or IFRS, are not reported by all of AkzoNobel’s or Axalta’s competitors and may not be directly comparable to similarly titled measures of AkzoNobel’s or Axalta’s competitors due to potential differences in the exact method of calculation.

AkzoNobel Contacts

Investor Contact
Kenny Chae
+31 (0)88 - 969 0139
[email protected]

Media Contact
Diana Abrahams
+31 (0)88 - 969 7833
[email protected]

Axalta Contacts

Investor Contact
Colleen Lubic
+1 (610) 999-9407
[email protected]

Media Contact
Patricia Morschel
+1 (302) 290-3906
[email protected]

______________________________

1 Includes approximately $600 million of run-rate synergies.
2 Adjusted Free Cash Flow calculated as reported Free Cash Flow including post-tax synergies and excluding identified items.
3 Combined financial figures do not include adjustments necessary to align to a consistent accounting standard or set of accounting policies. All combined company financial figures represent the addition of each company's as reported metrics inclusive of synergies where applicable.
2025-11-18 06:47 5mo ago
2025-11-18 01:01 5mo ago
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer stocknewsapi
ZYME
VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics today announced the appointment of Scott Platshon as Acting Chief Investment Officer.

Mr. Platshon will report directly to Zymeworks’ Chair and Chief Executive Officer, Kenneth Galbraith, and work closely with him to manage expected future cash flows from Ziihera® (zanidatamab-hrii) and other healthcare assets and licensed product candidates, such as pasritamig, which is being advanced to Phase 3 registration studies by Johnson & Johnson Innovative Medicine. He will also manage the operational execution of Zymeworks’ healthcare asset aggregation strategy.

Concurrent with this appointment, Mr. Platshon has stepped down from the Company’s Board of Directors. As this is a part-time role, he will also continue to serve as a Partner at EcoR1 Capital, LLC, a biotech-focused investment fund.

“Following the positive topline data from the Phase 3 HERIZON-GEA-01 trial evaluating zanidatamab in combination with chemotherapy with or without the PD-1 inhibitor Tevimbra® (tislelizumab), we are strategically positioned to drive long-term returns by building a diversified portfolio of revenue-generating assets,” said Mr. Galbraith. “Scott has played a key role in managing EcoR1’s investment in Zymeworks, including joining our Board in February 2024. He has been working closely with me and the Board to complement our active R&D operations with a novel strategic initiative of actively managing and aggregating revenue-generating assets to generate attractive long-term shareholder returns from an integrated business approach. Scott’s deep investment expertise, in-depth knowledge of the Company and our strategic objectives, and global network make him uniquely suited to help accelerate these efforts and protect and manage value arising from our royalty portfolio.”

Mr. Platshon has worked at EcoR1 Capital since 2015, and served as a Partner since 2020. Prior to joining the firm, he was an analyst at Aquilo Partners, a San Francisco-based boutique life sciences investment bank. Mr. Platshon also sits on the board of directors of Kumquat Biosciences and Ajax Therapeutics. Mr. Platshon holds a B.S. in Bioengineering from Stanford University.

“I am eager to continue working closely with Zymeworks, now in this new role, at such a pivotal moment, and share in the Company’s unified strategic vision to pursue innovation and growth,” said Scott Platshon. “The Company has built a strong financial foundation with Ziihera, its broader platform collaborations and wholly-owned R&D portfolio, and I see tremendous opportunity to leverage these cash flows to build a disciplined, high-return portfolio that creates sustainable value creation over the long-term. I look forward to enhancing my involvement within the Zymeworks team and forging new capital streams to deliver meaningful returns for shareholders.”

About Zymeworks Inc.

Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. The Company’s asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera® (zanidatamab-hrii), pasritamig, and other licensed products and product candidates, such as pasritamig. In addition, Zymeworks is also building a portfolio of healthcare assets that can generate strong cash flows, while supporting the early-stage development of innovative medicines. Zymeworks engineered and developed Ziihera® (zanidatamab-hrii), a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology and has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zymeworks is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.

Cautionary Note Regarding Forward-Looking Statements

This press release includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to Zymeworks’ expectations regarding implementation of its strategic priorities and the anticipated benefits thereof, including shareholder returns and the anticipated manner of such returns; implementation of its evolving asset aggregation strategy, including existing and potential future royalty streams and existing and potential new partnerships; statements that relate to the expected contributions of personnel to Zymeworks’ strategic goals; the anticipated benefits of its collaboration agreements, including Zymeworks’ ability to receive any future milestone payments and royalties thereunder; anticipated capital allocation strategy; industry opportunities for acquisition of new revenue streams or collaborations; the potential addressable market of zanidatamab; expected financial performance and future financial position; the commercial potential of technology platforms and product candidates; Zymeworks’ ability to satisfy potential regulatory and commercial milestones with existing and future partners; anticipated continued receipt of revenue from existing and future partners; Zymeworks’ early-stage pipeline and other information that is not historical information. When used herein, words such as “plan”, “believe”, “expect”, “may”, “continue”, “anticipate”, “potential”, “will”, “on track”, “progress”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: any of Zymeworks’ or its partners’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; Zymeworks may not achieve milestones or receive additional payments under its collaborations; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions, including the impact of tariffs; potential negative impacts of FDA regulatory delays and uncertainty around recent policy developments, changes in the leadership of federal agencies such as the FDA, staff layoffs, budget cuts to agency programs and research, and changes in drug pricing controls; the impact of pandemics and other health crises on Zymeworks’ business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks’ behalf; zanidatamab may not be successfully commercialized; Zymeworks’ evolution of its business strategy related to anticipated and potential future milestones and royalty streams and existing and potential new partnerships may not be successfully implemented; Zymeworks’ evolution of its business strategy may not deliver meaningful shareholder returns; Zymeworks may be unsuccessful in actively managing and/or aggregating revenue-generating assets alongside its active R&D operations; ongoing and future clinical trials may not demonstrate safety and efficacy of any of Zymeworks’ or its collaborators’ product candidates; Zymeworks’ assumptions and estimates regarding its financial condition, future financial performance and estimated cash runway may be incorrect; inability to maintain or enter into new partnerships or strategic collaborations; and the factors described under “Risk Factors” in Zymeworks’ quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at www.sec.gov and www.sedarplus.ca).

Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.

Investor inquiries:
Shrinal Inamdar
Senior Director, Investor Relations
(604) 678-1388
[email protected]

Media inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
[email protected]
2025-11-18 06:47 5mo ago
2025-11-18 01:01 5mo ago
As wellness trends go upscale, Nestle's mass-market vitamins lose some shine stocknewsapi
NSRGF NSRGY
Nestle wants out of mass-market vitamins. But a move by consumers towards more expensive, science-backed products risks complicating the Swiss conglomerate's effort to fetch a high price for its underperforming brands.
2025-11-18 06:47 5mo ago
2025-11-18 01:02 5mo ago
BW LPG Limited – Q3 2025 Financial Report Release and Earnings Presentation on 2 December 2025 stocknewsapi
BWLP
SINGAPORE--(BUSINESS WIRE)--BW LPG Limited (“BW LPG”, the “Company”, OSE ticker code: “BWLPG.OL”, NYSE ticker code: “BWLP”), the owner and operator of the world's largest fleet of Very Large Gas Carriers (VLGCs), announces today that it will release its Q3 2025 Financial Report at approximately 07:00hrs CET/ 01:00hrs EST/ 14:00hrs SGT on 2 December 2025. In connection with this release, BW LPG will hold an Earnings Presentation with Kristian Sørensen (CEO) and Samantha Xu (CFO). The details are.
2025-11-18 06:47 5mo ago
2025-11-18 01:04 5mo ago
Amundi to buy 10% of Britain's ICG in private markets push stocknewsapi
AMDUF
Amundi is buying a 9.9% stake in London‑listed Intermediate Capital Group to expand in private markets under its new three‑year strategic plan, Europe's largest asset manager said on Tuesday.
2025-11-18 06:47 5mo ago
2025-11-18 01:05 5mo ago
Credit Agricole sets 2028 profit target above expectations, eyes more deals stocknewsapi
CRARY
Credit Agricole on Tuesday set out a new net profit target of more than 8.5 billion euros ($9.0 billion) by 2028, beating analyst expectations as investors track the French bank's interest in Italian lender Banco BPM.
2025-11-18 06:47 5mo ago
2025-11-18 01:05 5mo ago
Rio Tinto's Yarwun alumina refinery to slash production, prolonging plant life until 2035 stocknewsapi
RIO
Anglo-Australian mining giant Rio Tinto announced Tuesday that it will slash production at its Yarwun alumina refinery in Queensland by 40% starting next October in a move to prolong the facility's operational life. Rio decided against building a second waste facility at Yarwun, as it concluded the required substantial investment was not currently viable.
2025-11-18 06:47 5mo ago
2025-11-18 01:07 5mo ago
Catapult Sports Ltd (CAZGF) Q2 2026 Earnings Call Transcript stocknewsapi
CAZGF
Will Lopes
CEO, MD & Executive Director

Good morning, and welcome to Catapult's investor conference call for our first half FY '26 results. I have with me Bob Cruickshank, Catapult's Chief Financial Officer. This morning, Bob and I will present our results, our strategy and outlook and then take questions from participants on the call.

It has been a momentous 6 months for Catapult. Just half a year ago, we reported outstanding FY '25 results, meeting the high bar we had set for ourselves and building on the clear inflection point we had achieved in FY '24. Since then, we've continued to accelerate this trajectory. 5 months ago, we announced the acquisition of Perch, the global leader in velocity-based training, shaping the future of athlete monitoring in the weight room.

And just last month, we welcomed Impect, the world's foremost innovator in soccer scouting and tactical analytics, whose end-to-end intelligence platform delivers insights unmatched in the game. It's been an extraordinary stretch, one defined by progress, purpose and performance. And today, with another strong set of financial results, we reaffirm that same commitment to innovation and to the promise of what's still ahead.

As you can see on Slide 3, the first half brought another milestone. Our customer base has now grown to more than 5,000 teams worldwide, an increase of 400 teams in just 6 months. While our focus, as many of you know, remains squarely on our professional teams, it's encouraging to
2025-11-18 06:47 5mo ago
2025-11-18 01:10 5mo ago
Genentech's Giredestrant Becomes the First Oral SERD to Show Superior Invasive Disease-Free Survival in Early Breast Cancer stocknewsapi
RHHBY
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive Phase III results from the lidERA Breast Cancer study evaluating investigational giredestrant as an adjuvant endocrine treatment for people with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, early-stage breast cancer. The study met its primary endpoint at a pre-planned interim analysis, showing a statistically si.
2025-11-18 06:47 5mo ago
2025-11-18 01:15 5mo ago
ING Bank Śląski takes full control of Goldman Sachs TFI by acquiring remaining 55% stake stocknewsapi
ING
ING Bank Śląski takes full control of Goldman Sachs TFI by acquiring remaining 55% stake

ING announced today that ING Bank Śląski has reached an agreement with Goldman Sachs on the full acquisition of the Polish asset management company Goldman Sachs TFI. ING already owns 45% of the company and with acquiring the remaining 55% stake it brings its ownership to 100%. 

“As we observe both the growing affluence of Polish customers and important demographic shifts, we see that customers are more often looking for alternatives to traditional saving products. We want to meet their needs in a simple, digital and safe way,” said Michał Bolesławski, CEO of ING Bank Śląski. “We are placing increasing emphasis on Private Banking and investment solutions. Taking over full control of Goldman Sachs TFI further reinforces our position in the investment and retirement markets. Under the ING brand, we want to offer clients a comprehensive range of solutions – from deposits to investment products”.

Pinar Abay, global head of Retail Banking and member of ING Group’s Management Board Banking commented: “This transaction underscores our ambition to accelerate growth, increase impact and deliver value. Within our Growing the Difference strategy, we take this opportunity to improve our product offering in this important market and further diversify our income.”

Goldman Sachs TFI serves over 736,000 clients, managing open mutual funds within various asset classes and dedicated asset management portfolios. With a market share of around 12%, it holds the second position in the Polish market in terms of assets under management of capital market mutual funds. Assets under management in scope of the transaction amount to PLN 48 billion.

ING Bank Śląski holds the current 45% of Goldman Sachs TFI since 2019, via its subsidiary ING Investment Holding. Goldman Sachs Asset Management became a 55% shareholder of Goldman Sachs TFI in Poland following its acquisition of NN Investment Partners in 2022. ING has signed a preliminary sale purchase agreement for the 55% stake in Goldman Sachs TFI for PLN 396 million (approximately €93 million at the relevant exchange rate). ING expects that the transaction will reduce ING Bank Śląski’s consolidated total capital ratio and Tier 1 ratio by approximately 34 bps. The transaction will have a minimal impact on ING Group’s CET1 ratio. Completion of the transaction is expected in the first half of 2026, subject to customary regulatory approvals.

ING Bank Śląski is one of the largest banks in Poland. It serves over five million retail and corporate clients via its digital channels and its nationwide network of branches. As of end September 2025 customer deposits amounted to PLN 230 billion, while customer loans amounted to PLN 177 billion, making ING Bank Śląski the third biggest bank in Poland. ING Bank Śląski is part of ING Group, which holds 75% of the shares, with the remaining 25% held by minority shareholders through its listing on the Warsaw Stock Exchange.

Note for editors
For more on ING, please visit www.ing.com. Frequent news updates can be found in the Newsroom or via X @ING_news feed. Photos of ING operations, buildings and its executives are available for download at Flickr.

ING PROFILE
ING is a global financial institution with a strong European base, offering banking services through its operating company ING Bank. The purpose of ING Bank is: empowering people to stay a step ahead in life and in business. ING Bank’s more than 60,000 employees offer retail and wholesale banking services to customers in over 100 countries.

ING Group shares are listed on the exchanges of Amsterdam (INGA NA, INGA.AS), Brussels and on the New York Stock Exchange (ADRs: ING US, ING.N).

ING aims to put sustainability at the heart of what we do. Our policies and actions are assessed by independent research and ratings providers, which give updates on them annually. ING's ESG rating by MSCI has been upgraded from 'AA' to 'AAA' in October 2025. As of June 2025, in Sustainalytics’ view, ING’s management of ESG material risk is ‘Strong’ with an ESG risk rating of 18.0 (low risk). ING Group shares are also included in major sustainability and ESG index products of leading providers. Here are some examples: Euronext, STOXX, Morningstar and FTSE Russell. Society is transitioning to a low-carbon economy. So are our clients, and so is ING. We finance a lot of sustainable activities, but we still finance more that’s not. Follow our progress on ing.com/climate.

IMPORTANT LEGAL INFORMATION
Elements of this press release contain or may contain information about ING Groep N.V. and/ or ING Bank N.V. within the meaning of Article 7(1) to (4) of EU Regulation No 596/2014 (‘Market Abuse Regulation’).

ING Group’s annual accounts are prepared in accordance with International Financial Reporting Standards as adopted by the European Union (‘IFRS- EU’). In preparing the financial information in this document, except as described otherwise, the same accounting principles are applied as in the 2024 ING Group consolidated annual accounts. All figures in this document are unaudited. Small differences are possible in the tables due to rounding.

Certain of the statements contained herein are not historical facts, including, without limitation, certain statements made of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Actual results, performance or events may differ materially from those in such statements due to a number of factors, including, without limitation: (1) changes in general economic conditions and customer behaviour, in particular economic conditions in ING’s core markets, including changes affecting currency exchange rates and the regional and global economic impact of the invasion of Russia into Ukraine and related international response measures (2) changes affecting interest rate levels (3) any default of a major market participant and related market disruption (4) changes in performance of financial markets, including in Europe and developing markets (5) fiscal uncertainty in Europe and the United States (6) discontinuation of or changes in ‘benchmark’ indices (7) inflation and deflation in our principal markets (8) changes in conditions in the credit and capital markets generally, including changes in borrower and counterparty creditworthiness (9) failures of banks falling under the scope of state compensation schemes (10) non- compliance with or changes in laws and regulations, including those concerning financial services, financial economic crimes and tax laws, and the interpretation and application thereof (11) geopolitical risks, political instabilities and policies and actions of governmental and regulatory authorities, including in connection with the invasion of Russia into Ukraine and the related international response measures (12) legal and regulatory risks in certain countries with less developed legal and regulatory frameworks (13) prudential supervision and regulations, including in relation to stress tests and regulatory restrictions on dividends and distributions (also among members of the group) (14) ING’s ability to meet minimum capital and other prudential regulatory requirements (15) changes in regulation of US commodities and derivatives businesses of ING and its customers (16) application of bank recovery and resolution regimes, including write down and conversion powers in relation to our securities (17) outcome of current and future litigation, enforcement proceedings, investigations or other regulatory actions, including claims by customers or stakeholders who feel misled or treated unfairly, and other conduct issues (18) changes in tax laws and regulations and risks of non-compliance or investigation in connection with tax laws, including FATCA (19) operational and IT risks, such as system disruptions or failures, breaches of security, cyber-attacks, human error, changes in operational practices or inadequate controls including in respect of third parties with which we do business and including any risks as a result of incomplete, inaccurate, or otherwise flawed outputs from the algorithms and data sets utilized in artificial intelligence (20) risks and challenges related to cybercrime including the effects of cyberattacks and changes in legislation and regulation related to cybersecurity and data privacy, including such risks and challenges as a consequence of the use of emerging technologies, such as advanced forms of artificial intelligence and quantum computing (21) changes in general competitive factors, including ability to increase or maintain market share (22) inability to protect our intellectual property and infringement claims by third parties (23) inability of counterparties to meet financial obligations or ability to enforce rights against such counterparties (24) changes in credit ratings (25) business, operational, regulatory, reputation, transition and other risks and challenges in connection with climate change, diversity, equity and inclusion and other ESG-related matters, including data gathering and reporting and also including managing the conflicting laws and requirements of governments, regulators and authorities with respect to these topics (26) inability to attract and retain key personnel (27) future liabilities under defined benefit retirement plans (28) failure to manage business risks, including in connection with use of models, use of derivatives, or maintaining appropriate policies and guidelines (29) changes in capital and credit markets, including interbank funding, as well as customer deposits, which provide the liquidity and capital required to fund our operations, and (30) the other risks and uncertainties detailed in the most recent annual report of ING Groep N.V. (including the Risk Factors contained therein) and ING’s more recent disclosures, including press releases, which are available on www.ING.com.

This document may contain ESG-related material that has been prepared by ING on the basis of publicly available information, internally developed data and other third-party sources believed to be reliable. ING has not sought to independently verify information obtained from public and third-party sources and makes no representations or warranties as to accuracy, completeness, reasonableness or reliability of such information. This document may also discuss one or more specific transactions and/or contain general statements about ING’s ESG approach. The approach and criteria referred to in this document are intended to be applied in accordance with applicable law. Due to the fact that there may be different or even conflicting laws, the approach, criteria or the application thereof, could be different.

Materiality, as used in the context of ESG, is distinct from, and should not be confused with, such term as defined in the Market Abuse Regulation or as defined for Securities and Exchange Commission (‘SEC’) reporting purposes. Any issues identified as material for purposes of ESG in this document are therefore not necessarily material as defined in the Market Abuse Regulation or for SEC reporting purposes. In addition, there is currently no single, globally recognized set of accepted definitions in assessing whether activities are “green” or “sustainable.” Without limiting any of the statements contained herein, we make no representation or warranty as to whether any of our securities constitutes a green or sustainable security or conforms to present or future investor expectations or objectives for green or sustainable investing. For information on characteristics of a security, use of proceeds, a description of applicable project(s) and/or any other relevant information, please reference the offering documents for such security.

This document may contain inactive textual addresses to internet websites operated by us and third parties. Reference to such websites is made for information purposes only, and information found at such websites is not incorporated by reference into this document. ING does not make any representation or warranty with respect to the accuracy or completeness of, or take any responsibility for, any information found at any websites operated by third parties. ING specifically disclaims any liability with respect to any information found at websites operated by third parties. ING cannot guarantee that websites operated by third parties remain available following the publication of this document, or that any information found at such websites will not change following the filing of this document. Many of those factors are beyond ING’s control.

Any forward-looking statements made by or on behalf of ING speak only as of the date they are made, and ING assumes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information or for any other reason.

This document does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities in the United States or any other jurisdiction.

PDF version of press release
2025-11-18 06:47 5mo ago
2025-11-18 01:17 5mo ago
XP Inc. (XP) Q3 2025 Earnings Call Transcript stocknewsapi
XP
Q3: 2025-11-17 Earnings SummaryEPS of $0.46 beats by $0.01

 |

Revenue of

$875.65M

(17.04% Y/Y)

beats by $13.97M

XP Inc. (XP) Q3 2025 Earnings Call November 17, 2025 5:00 PM EST

Company Participants

Andre Parize - Chief Investor Relations Officer
Thiago Maffra - Chief Executive Officer
Victor Mansur - Chief Financial Officer

Conference Call Participants

Eduardo Rosman - Banco BTG Pactual S.A., Research Division
Yuri Fernandes - JPMorgan Chase & Co, Research Division
Mario Pierry - BofA Securities, Research Division
Gustavo Schroden - Citigroup Inc., Research Division
Daniel Vaz - J. Safra Corretora de Valores e Cambio Ltda, Research Division
Thiago Bovolenta Batista - UBS Investment Bank, Research Division
Daer Labarta - Goldman Sachs Group, Inc., Research Division
Marcelo Mizrahi - Banco Bradesco BBI S.A., Research Division

Presentation

Andre Parize
Chief Investor Relations Officer

Good evening, everyone. I'm Andre Parize. Investor Relations Officer at XP. And it's a pleasure to be here with you today. On behalf of the company, I would like to thank you all for your interest and welcome you to our third quarter 2025 earnings call.

Today's presentation will be led by our CEO, Thiago Maffra, and our CFO, Victor Mansur, who will both be available for the Q&A session right after the presentation.

If you would like to ask a question, please use the raise hand feature on Zoom, and we will address them in the order we received. [Operator Instructions].

Before we begin, please refer to our legal disclaimers on Page 2, where we provide additional information regarding forward-looking statements. You can also find more information in the SEC filings section on our IR website.

Now I'll turn it over to Thiago Maffra. Good evening, Maffra.

Thiago Maffra
Chief Executive Officer

Thank you, Andre. Good evening, everyone. I appreciate you all joining us today for the third quarter 2025 earnings call. 2025 has been a very important year for XP as we have achieved significant progress on our agenda of excellence from the launch of

Recommended For You
2025-11-18 06:47 5mo ago
2025-11-18 01:18 5mo ago
Pagaya Technologies Understands The Role Of AI In Credit Underwriting stocknewsapi
PGY
Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in PGY over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
2025-11-18 06:47 5mo ago
2025-11-18 01:24 5mo ago
Alm. Brand Group hosts Capital Markets Day and releases financial targets for 2028 stocknewsapi
ABDBY
Today, Alm. Brand Group will host a Capital Markets Day to present its new strategy Unfolding the scale potential and financial targets for 2028.

Financial targets towards 2028

Following the successful integration of Codan with realisation of synergies and establishing one unified insurance platform, the foundation is now set to unfolding the scale potential as a large dedicated Danish non-life insurer. In the new strategy period (2026-2028), Alm. Brand Group expects to create significant gains from operational efficiencies, leading to a target for the insurance service result of DKK 2,350 million including run-off gains in 2028. The target insurance service result in 2028 is DKK 500 million above the target for 2025.

For the insurance operations, Alm. Brand Group targets to reduce the combined ratio to 82 in 2028, including a reduction of the expense ratio to 16.

Alm. Brand Group remains committed to distribute a high proportion of future earnings to its shareholders. Therefore the group maintains its distribution policy with a payout ratio of at least 80% and expects the distribution in the coming years to continue to be a combination of dividend payments and share buy-backs.

The expansion of the partial internal model (PIM) reduces the capital requirement and paves the way for additional share buy-backs of DKK 600 million, expected to be initiated in 2026. To maintain a strong and sustainable capital position, the capital target is raised from 170% to 180% of the solvency capital requirement.

The strategic initiatives combined with buybacks are anticipated to drive annual growth in earnings per share of 10% on average in the period 2026 to 2028. In addition, Alm. Brand Group introduces a new profitability target, Return on Own Funds (RoOF), with a target of 40% to be achieved by 2028.

Today’s presentation is available investorrelations.almbrand.dk/Capital-Market-Update. The Capital Markets Day will be live webcasted from 10:30 a.m. to around 1:00 p.m. (CET) and will subsequently be made available here.

Contact

Please direct any questions regarding this announcement to:

Investors and equity analysts:                       

Head of IR & ESG                                          Senior Investor Relations Officer
Mads Thinggaard                                           Nikolaj Albert Moldrup Thalbitzer
Mobile no. +45 20 25 54 69                           Mobile no. +45 20 60 57 84

Press:                                                                                      

Head of Communications and Media Relations
Mikkel Luplau Schmidt
Mobile no. +45 20 52 38 83

AS 77 2025 - Alm. Brand Group hosts Capital Markets Day and releases financial targets for 2028

Alm. Brand - CMD 2025 - Unfolding the scale potential
2025-11-18 06:47 5mo ago
2025-11-18 01:31 5mo ago
AkzoNobel, Axalta to Merge in $25 Billion All-Stock Deal Including Debt stocknewsapi
AKZOY AXTA
The merger is set to create a global coatings giant that is expected to generate $17 billion in annual revenue.
2025-11-18 06:47 5mo ago
2025-11-18 01:33 5mo ago
Nio's Firefly EV brand seeks growth in right-hand drive markets without tariffs stocknewsapi
NIO
Firefly, a compact electric vehicle brand owned by China's Nio , is seeking growth in right-hand drive markets that are free from punitive tariffs on Chinese EVs and is preparing to ramp up deliveries to those destinations next year.
2025-11-18 06:47 5mo ago
2025-11-18 01:40 5mo ago
AMDY Performing Well In A Challenging Market stocknewsapi
AMDY
Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
2025-11-18 06:47 5mo ago
2025-11-18 01:45 5mo ago
Trifork partners with Loft Dynamics to scale qualified pilot training on Apple Vision Pro stocknewsapi
AAPL
Press release

Trifork partners with Loft Dynamics to scale qualified pilot training on Apple Vision Pro

San Francisco and Dübendorf, Switzerland — November 18, 2025 — Loft Dynamics, the pioneer behind the world’s first EASA- and FAA-qualified virtual reality flight simulators, announced a strategic partnership with Trifork, a global technology company and leader in spatial computing. Together, the companies are developing an industry-defining solution called LoftHOME, an at-home pilot training kit that extends Loft Dynamics’ qualified training ecosystem to Apple Vision Pro. This will allow Loft Dynamics to bring its high-fidelity, regulator-approved flight instruction to pilots anywhere, anytime and at scale.

For decades, pilot training has relied on full-motion simulators, which are trusted but costly and cumbersome, limited in number, and often far from where pilots live and work. That model restricts how often pilots can train and how flexibly operators can schedule instruction. LoftHOME aims to change that by delivering the same realism and rigor trusted by regulators in a flexible, immersive format on Apple Vision Pro.

LoftHOME: A seamless training flow from home to simulator and back 

The LoftHOME experience follows the complete training flow, from cockpit familiarization and procedure rehearsal in an immersive 3-D environment to briefing, in-simulator instruction, and post-simulator debriefing. It can be used with or without a Loft Dynamics simulator. Pilots and instructors can even join simulator sessions remotely, using the same software and environments found in Loft Dynamics’ full-motion simulators. The result is a seamless, connected learning journey that extends from home to training center and back again.

A shared vision for accessible, continuous training

“Our vision has always been to make the highest-quality pilot training safe and universally accessible,” said Fabi Riesen, founder and CEO of Loft Dynamics. “With Trifork, we’re bringing incredibly realistic, regulator-backed training into pilots’ everyday environments via Apple Vision Pro, from their living rooms to the airport gate. The goal isn’t just convenience; it’s continuity: a connected training ecosystem that links remote rehearsal with qualified simulator instruction, empowering pilots, instructors, and operators to train more often and more effectively. Trifork is the ideal partner to help scale this vision and deliver lasting impact across the aviation ecosystem.”

Engineering scale meets regulatory trust

“Trifork is pioneering spatial computing solutions that reshape how enterprises learn, train, and operate,” said Karan Yadav, CEO of Trifork North America and global lead for spatial computing. “Our work with organizations like Lufthansa Aviation Training shows how immersive tools can create real operational gains. This partnership with Loft Dynamics enables a new, flexible training model that can expand from initial skills development to regulated, multi-crew, airline-level instruction, all with a flexible, efficient and scalable spatial computing solution.”

What’s next?

Loft Dynamics and Trifork will launch pilot programs for LoftHOME with select airlines and training centers before expanding to additional use cases, including aircraft transition, multi-crew cooperation, and operational and emergency procedures. Each is designed to connect at-home rehearsal with in-center, regulator-credited training.

About Loft Dynamics

Loft Dynamics AG is the global leader in virtual reality (VR) flight training, and the first company with VR simulators qualified by both the FAA and EASA. Trusted by Alaska Airlines, Airbus Helicopters, the Los Angeles Police Department, and more, we serve the full aviation ecosystem – spanning commercial airlines, eVTOLs, and diverse helicopter operators, as well as schools, OEMs, governments, and regulators. Our mission is to make pilot training safer and more accessible, affordable and scalable than ever before. We produce full-motion VR simulators for helicopters, airlines, and eVTOLs that are ten times smaller and significantly more cost-effective than legacy simulators. We also provide a connected suite of solutions that integrate our simulators worldwide, including at-home training kits, virtual instruction from the world’s top pilots and AI-driven training intelligence. Loft Dynamics is leading a global paradigm shift in pilot training and powering the next generation of highly skilled pilots. Learn more at LoftDynamics.com.

Contact: [email protected]

About Trifork Group

Trifork (Nasdaq Copenhagen: TRIFOR) is a pioneering global technology company, empowering enterprise and public sector customers with innovative digital products and solutions. With 1,197 employees across 16 countries, Trifork specializes in designing, building, and operating advanced software in public administration, healthcare, financial services, manufacturing, energy, aviation, and retail. The Group’s R&D arm, Trifork Labs, drives innovation by investing in and developing synergistic, high-potential technology companies. Learn more at trifork.com.

Contact: Frederik Svanholm, Group Investment Director, +41 79 357 7317, [email protected]

Loft Dynamics partnership
2025-11-18 05:47 5mo ago
2025-11-17 23:32 5mo ago
Why Bitcoin slipped to $90,000? cryptonews
BTC
Bitcoin's slide below the $90,000 threshold has deepened a month-long downturn that has erased the cryptocurrency's gains for 2025 and unsettled sentiment across the digital-asset landscape.
2025-11-18 05:47 5mo ago
2025-11-17 23:34 5mo ago
OKX to Launch Horizen (ZEN) Spot Trading cryptonews
ZEN
Iris Coleman
Nov 18, 2025 05:34

OKX has announced the listing of Horizen (ZEN) for spot trading, with deposits opening on November 17, 2025, and trading commencing the following day.

OKX, a leading cryptocurrency exchange, has announced the addition of Horizen (ZEN) to its spot trading platform. This move underscores OKX's commitment to expanding its range of tradable digital assets, according to OKX.

Listing Timeline
The listing process for Horizen (ZEN) is set to unfold over several phases. Deposits for ZEN began at 13:00 UTC on November 17, 2025. A pre-open session is scheduled from 5:00 to 6:00 UTC on November 18, 2025, allowing traders to prepare for the market. Spot trading for the ZEN/USDT pair will commence at 6:00 UTC on the same day, with withdrawals becoming available at 8:00 UTC.

Risk Control Measures
OKX has implemented robust risk control measures to ensure a stable trading environment. The platform will employ index-based price limit rules during both the pre-open session and continuous trading. These rules are designed to mitigate volatility and protect traders from extreme market fluctuations. OKX has stated that it may adjust parameters or switch calculation methods based on market conditions without prior notice.

About Horizen
Horizen is a blockchain ecosystem that emphasizes privacy and scalability through the use of side chains. It provides a flexible platform for businesses and developers to create both public and private blockchains, as well as decentralized applications. The asset is identified by the ticker ZEN, and operates on a base chain with the contract address 0xf43eb8de897fbc7f2502483b2bef7bb9ea179229.

Market Implications
The inclusion of Horizen on OKX's trading platform is expected to enhance liquidity and accessibility for ZEN, potentially attracting a broader investor base. This listing could be particularly beneficial for traders looking to diversify their portfolios with privacy-focused blockchain assets.

OKX continues to expand its offerings, keeping pace with the evolving demands of the cryptocurrency market. By integrating Horizen, the exchange not only broadens its asset portfolio but also reaffirms its position as a versatile trading platform catering to diverse investor interests.

Image source: Shutterstock

okx
horizen
zen
spot trading
2025-11-18 05:47 5mo ago
2025-11-17 23:41 5mo ago
IOTA Partners with Global Entities for Africa's Digital Trade Transformation cryptonews
IOTA
Terrill Dicki
Nov 18, 2025 05:41

IOTA collaborates with the World Economic Forum and Tony Blair Institute on ADAPT, aiming to revolutionize Africa's trade through digital infrastructure.

IOTA has announced a significant partnership with the World Economic Forum and the Tony Blair Institute for Global Change to launch ADAPT, a groundbreaking pan-African digital trade initiative. Spearheaded by the African Continental Free Trade Area (AfCFTA), ADAPT aims to streamline identity, data, and finance through a robust digital public infrastructure, according to the IOTA Blog.

Transforming Africa's Trade Landscape
Africa is on the brink of a transformative trade evolution that could significantly influence its economic future. The ADAPT initiative is set to digitize the continent's trade processes, enhancing the movement of goods, data, and payments. This digital transformation is projected to unlock tens of billions of dollars in new trade value and bolster economic inclusion across Africa.

The initiative envisions a future where all African countries are integrated into a single open digital infrastructure by 2035. This integration is expected to double intra-African trade, unlocking over $70 billion in additional annual trade and generating $23.6 billion in annual economic gains from expedited and cost-effective trade processes.

Overcoming Trade Barriers
Despite Africa's vast potential, intra-African trade accounts for only 17% of the continent's total trade, a stark contrast to regions like Asia and Europe where it exceeds 60%. Structural inefficiencies, such as the lack of trusted digital identities and secure data exchanges, have been significant barriers. Paper-based documentation and lengthy border clearance times further exacerbate these challenges, costing African economies an estimated $25 billion annually.

ADAPT addresses these challenges by providing a digital platform that facilitates seamless trade. The initiative is backed by the AfCFTA Secretariat, IOTA, the Tony Blair Institute for Global Change, and the World Economic Forum, aiming to set a global benchmark for digital innovation in trade.

Key Digital Deliverables
ADAPT's framework is built upon three interconnected layers: identity, data, and finance. It will enable businesses and governments to adopt secure, self-sovereign digital identities and facilitate cross-border data exchanges. The initiative also aims to create an interoperable finance layer that connects mobile money, banks, and digital currencies, reducing transaction costs and clearance times.

This technological infrastructure will unlock billions in trade finance for small and medium enterprises, ensuring that trusted information flows as efficiently as goods across borders.

Technological Backbone and Implementation
The technological vision for ADAPT includes leveraging emerging technologies like IOTA's public blockchain network to ensure interoperability across existing systems. IOTA's expertise will be instrumental in building and integrating ADAPT, transforming trade by converting shipments, documents, and transactions into verifiable digital data.

The rollout of ADAPT will occur in phases, starting with pilot programs in countries like Kenya and Ghana from 2025 to 2026, followed by broader continental implementation by 2035. This phased approach invites collaboration from investors, innovators, and development partners to build a robust foundation for Africa's digital trade economy.

IOTA's commitment to Africa extends beyond ADAPT, with plans to hire specialists, build decentralized infrastructures, and foster local innovation through events and partnerships. This holistic approach aims to position Africa as a leader in digital trade transformation.

Image source: Shutterstock

iota
africa
digital trade
blockchain
2025-11-18 05:47 5mo ago
2025-11-17 23:44 5mo ago
El Salvador Buys the Dip, Accumulates 1,098 BTC in 7 Days cryptonews
BTC
El Salvador has purchased 1098.19 BTC over the past 7 days, increasing its total holdings to 7474.37 BTC, worth $688 million.
2025-11-18 05:47 5mo ago
2025-11-17 23:49 5mo ago
Bitcoin drops below $90,000 in sign of souring mood cryptonews
BTC
Bitcoin slipped below $90,000 for the first time in seven months on Tuesday in the latest sign that investor appetite for risk-taking is drying up across financial markets.
2025-11-18 05:47 5mo ago
2025-11-17 23:55 5mo ago
Mt. Gox moves $936M in Bitcoin after eight-month dormancy cryptonews
BTC
The recent wallet activity signals progress in creditor repayments as legal proceedings and asset management efforts continue for Mt. Gox.

Key Takeaways

Mt. Gox moved $936 million in Bitcoin after eight months of inactivity.
The movement relates to the exchange's ongoing court-supervised creditor repayment process.

Mt. Gox, the defunct crypto exchange, moved $936 million worth of Bitcoin today after remaining dormant for eight months. The transfer involved shifting Bitcoin to a new wallet address, marking the first major activity from the exchange’s holdings since March.

The movement comes as Mt. Gox continues its court-supervised creditor repayment process. The rehabilitation trustee has extended the deadline for creditor reimbursements to allow more time for managing Bitcoin distributions.

Mt. Gox has been gradually shifting Bitcoin to new addresses as part of its ongoing efforts to repay creditors. The exchange collapsed in 2014 following a massive hack that resulted in the loss of around 850,000 Bitcoin.

The latest wallet activity suggests preparations may be underway for additional creditor payments, though the exchange has not disclosed specific timelines for distributions. Mt. Gox began returning funds to creditors in 2024 after years of legal proceedings.

Disclaimer
2025-11-18 05:47 5mo ago
2025-11-17 23:56 5mo ago
Gemini's Cameron Winklevoss Flags Bitcoin's Sub-$90K Level as Rare Buying Opportunity cryptonews
BTC
Gemini's Cameron Winklevoss said Bitcoin under $90K may be a final buying chance as the token slid from its $126K peak to the low $90Ks.
2025-11-18 05:47 5mo ago
2025-11-17 23:58 5mo ago
[LIVE] Crypto News Today: Latest Updates for Nov. 18, 2025 – Market Correction Deepens: BTC Below $90K, ETH Under $3K, Layer-2s Hammered 7% cryptonews
BTC ETH
Follow up to the hour updates on what is happening in crypto today, November 18. Market movements, crypto news, and more!
2025-11-18 05:47 5mo ago
2025-11-18 00:00 5mo ago
Bitcoin's 2025 gains no more as Peter Schiff slams Strategy's ‘fraud' model cryptonews
BTC
Journalist

Posted: November 18, 2025

Key Takeaways
Why does he believe Strategy’s model is a ‘fraud’?
According to Schiff, it lacks sufficient operating earnings to cover its leveraged bet on BTC. 

Which line will hold BTC’s plunge?
Per QCP Capital, the next support levels on the charts worth tracking are $92k and $80k. 

Bitcoin’s [BTC] 2025 gains of 28% have been erased after the weekend’s extended correction to $95k. 

Unsurprisingly, with the underperformance, BTC, alongside its high-beta Strategy (Nasdaq: MSTR), has become a punching bag for Peter Schiff – A long-time critic and pro-gold investor. 

In an X post (formerly Twitter), Schiff called Strategy’s business model, read BTC arbitrage, a ‘fraud’ that will eventually go bankrupt.  

Source: X

His argument? Strategy has no operating earnings to cover the debt it has taken on by betting on BTC. 

Strategy’s debt profile
Since 2020, Strategy has accumulated a total of 641,692 BTC, worth $61 billion at press time market prices. The stash has been bought via debt and the sale of MSTR and other preferred stocks. The holdings currently have an unrealized profit of $13 billion. 

On the debt side, Strategy owes $8.2 billion with the first maturity expected in H2 2028. Approximately half of the total debt is expected to be cleared by 2028/2029. 

Source: Strategy

So, that’s three years out, and it’s not a near-term concern.

Besides, the argument that Strategy has no operating cash flow is flawed, according to Jeff Dorman, CIO of digital investment firm Arca.

Dorman rebuffed even the rumors that Strategy would be forced to sell BTC if the debt maturity were hit, citing Saylor’s ownership control. He added, 

“There are no covenants in the debt that force a sale. Interest expense is low and manageable – don’t forget the core tech business still has positive cash flow.”

Schiff also took a swipe at BTC’s relative underperformance to gold, which climbed above $4,100 again as crypto slipped lower. He urged his followers to “sell Bitcoin now and buy gold before you get mauled.”

Source: BTC/gold ratio, TradingView 

On this point, he is right – BTC has lagged behind gold since August. However, when zoomed out, it has been consolidating between 20-37 levels of the BTC/gold ratio, the indicator that tracks relative performance between the two commodities.

Whether it will be a bearish or bullish (BTC outperformance) breakout remains to be seen. 

That being said, QCP Capital has stated there is still heavy BTC positioning for the downside, eyeing a potential reversal at $92k or $80k. 

“Key support sits at $92k, the same base from Q4 last year, with an unfilled CME gap likely to attract buyers, though dense overhead supply limits any bounce.”
2025-11-18 05:47 5mo ago
2025-11-18 00:00 5mo ago
Uniswap – How heavy selling pressure might undo UNI's latest price breakout cryptonews
UNI
Journalist

Posted: November 18, 2025

Key Takeaways
Will UNI’s uptrend continue now?
It might, but the lack of demand and on-chain accumulation may be a worrying sign of weakness from the buyers.

What can investors expect next?
The $8-$8.6 resistance zone will be a tough nut to crack. Underwater holders would add to the selling pressure if they look to exit the market at break-even. 

On Monday, 17 November, Lookonchain reported that a wallet linked to Amber Group had accumulated 1.41 million Uniswap [UNI] tokens. The analysis went further, noting that 1.39 million tokens were deposited to Coinbase Prime, likely for custody.

Accumulation of this kind is encouraging news. Earlier this month, UNI saw a rally from $4.73 to $10.3. It broke a key swing level at $8.6, and shifted the market structure on the 1-day timeframe bullishly.

An AMBCrypto report last week highlighted that a price dip to $6.86 might be likely at that time. This price dip has since come to pass, and Uniswap has bounced by 8.9% in the last four days. Now, the $8-level serves as resistance to the bulls.

At the time of writing, on-chain metrics indicated there’s a good chance of further gains. However, the selling pressure, despite the upward price trend, might be a worry.

Difficulties ahead for Uniswap bulls
On 11 November, when Uniswap was trading at $10, the mean coin age saw a sizeable drop. At the same time, the age consumed metric jumped higher. Together, these two metrics revealed a flurry of previously dormant tokens being moved on-chain.

This kind of movement generally reflects selling intent, and may be followed by a price correction to $6.86. During and after this correction, it was hoped that the mean coin age would begin to trend higher again.

It did not, and it has slowly slid lower. This lack of network-wide accumulation seemed to be a sign that investors on-chain did not believe in the bullish chances of UNI. The MVRV ratio fell into negative territory too to show that holders were, on average, facing a loss.

The lack of confidence and holders at a loss mean that any price bounce could run into selling pressure from holders trying to exit at break-even.

Finally, the exchange netflow metric for the token showed high inflows on 10-11 November, in agreement with AMBCrypto’s assessment of a hike in sell pressure.

On a positive note, the 10k-1M UNI holding wallets have grown in number over the last two months. Not all whale wallets have bought more UNI. However, the behavior of this cohort is still interesting.

Source: UNI/USDT on TradingView

Despite the bullish daily structure, the OBV appeared to be in a severe downtrend at press time. It made a lower low during the retracement, highlighting heavy sell pressure.

Unless organic demand grows quickly, it might be difficult for bulls to keep the rally going beyond the $8-$8.6 resistance zone.
2025-11-18 05:47 5mo ago
2025-11-18 00:00 5mo ago
Analyst Shares Worst-Case Scenario For Bitcoin (BTC) As Price Shows Concerning Signs cryptonews
BTC
While Bitcoin (BTC) continues to lose crucial support levels, an analyst has shared three possible scenarios for the flagship crypto’s upcoming performance, raising the alarm about potential early signs of a bear market.

Bitcoin Price Correction Continues
On Monday, Bitcoin reached a new multi-month low after dropping below $93,000 for the first time since May. The cryptocurrency started the week dropping nearly 5% from the $96,000 area and retesting the $91,000 level as support.

Notably, BTC has seen a 16% correction from its November opening and has lost multiple crucial levels over the past few weeks, including the $100,000 psychological barrier and the 21-Week Exponential Moving Average (EMA) as support.

Most recently, the flagship cryptocurrency closed the week below the 50-week EMA, which has raised the alarm for several market observers.

Analyst Rekt Capital noted that losing this indicator is “not something we typically want to see if bullish Market Structure is to remain intact,” adding that “bear markets tend to confirm when price loses the key bullish levels that have supported upside momentum across the cycle.”

BTC loses the 50-Week EMA as support. Source: Rekt Capital
He explained that Bitcoin has formed clusters of lower lows at the 50-Week EMA across the cycle, which have “helped sustain a broader bullish technical uptrend.” However, BTC is currently forming another cluster below this indicator, instead of approaching the possible macro lower high developing above the 50-Week EMA.

As a result, BTC’s recent performance signals the first step of a potential breakdown, the analyst warned:

A full breakdown unfolds in three parts: first, a Weekly Close below the key level; second, a post-breakdown relief rally that turns that level into new resistance; and third, downside continuation that completes the bearish confirmation.

Early Signs Of A Bearish Trend?
Rekt Capital stressed that the 50-week EMA will be crucial in determining whether BTC’s bullish trend and tendency for “benign downside deviations” still hold.

He emphasized that if the flagship crypto fails to reclaim this indicator as support and it turns into a resistance, it could be transitioning from its downside deviation tendency to the early stages of a confirmed bearish trend.

The analyst detailed that during the early bear markets, “a Weekly Close below the 50-Week EMA is followed by several weeks of post-breakdown relief rallies into that moving average, but those attempts ultimately fail, and the EMA simply acts as resistance until downside acceleration unfolds.”

Based on this, he shared three potential outlooks for BTC’s performance. The best-case scenario for Bitcoin would be reclaiming this indicator and successfully ending this correction as a downside deviation, as it would suggest that BTC remains in a bull market.

The second-best case scenario would be that Bitcoin sees a multi-week hesitation period below the EMA as it enters the bear market, which could include a brief overextension above this level before a clearer trend resolution to the downside.

Meanwhile, the worst-case scenario would see the cryptocurrency’s price unable to retest the 50-Week EMA, even as resistance, and directly enter the downside acceleration phase.

Nonetheless, the analyst noted that, historically, the third scenario doesn’t appear as likely if we have already entered a bear market. Instead, he concluded that the recurring “relief-rally scenario” into the 50-week EMA before downside continuation seems more likely.

Bitcoin’s performance in the one-week chart. Source: BTCUSDT on TradingView
Featured Image from Unsplash.com, Chart from TradingView.com
2025-11-18 05:47 5mo ago
2025-11-18 00:01 5mo ago
Bitcoin dips below $90,000, marking ‘significant' psychological break: analysts cryptonews
BTC
One analyst noted $80,000 as a critical threshold, where a break below could lead to lows of around $74,000 seen in February.
2025-11-18 05:47 5mo ago
2025-11-18 00:08 5mo ago
Solana (SOL) Extends Sell-Off to $130 as Recovery Attempts Remain Fragile cryptonews
SOL
Solana started a fresh decline below the $145 zone. SOL price is now consolidating losses below $140 and might decline further below $130.

SOL price started a fresh decline below $145 and $140 against the US Dollar.
The price is now trading below $140 and the 100-hourly simple moving average.
There is a key bearish trend line forming with resistance at $136 on the hourly chart of the SOL/USD pair (data source from Kraken).
The price could start a recovery wave if the bulls defend $130 or $128.

Solana Price Dips Further
Solana price failed to remain stable above $155 and started a fresh decline, like Bitcoin and Ethereum. SOL declined below the $150 and $140 support levels.

The price gained bearish momentum below $138. A low was formed at $128, and the price is now consolidating losses. The price recovered a few points above the 23.6% Fib retracement level of the downward move from the $143 swing high to the $128 low.

Solana is now trading below $140 and the 100-hourly simple moving average. On the upside, immediate resistance is near the $136 level. There is also a key bearish trend line forming with resistance at $136 on the hourly chart of the SOL/USD pair.

Source: SOLUSD on TradingView.com
The next major resistance is near the $140 level or the 76.4% Fib retracement level of the downward move from the $143 swing high to the $128 low. The main resistance could be $142. A successful close above the $142 resistance zone could set the pace for another steady increase. The next key resistance is $150. Any more gains might send the price toward the $155 level.

Another Decline In SOL?
If SOL fails to rise above the $140 resistance, it could continue to move down. Initial support on the downside is near the $130 zone. The first major support is near the $128 level.

A break below the $128 level might send the price toward the $120 support zone. If there is a close below the $120 support, the price could decline toward the $108 support in the near term.

Technical Indicators

Hourly MACD – The MACD for SOL/USD is gaining pace in the bearish zone.

Hourly Hours RSI (Relative Strength Index) – The RSI for SOL/USD is below the 50 level.

Major Support Levels – $130 and $128.

Major Resistance Levels – $136 and $140.
2025-11-18 05:47 5mo ago
2025-11-18 00:20 5mo ago
Bitcoin Dips Under $90K, but Bulls Are Still Unfazed cryptonews
BTC
Bitcoin continued its downtrend on Monday night, falling under $90K for the first time in seven months as a bearish sentiment gets hold of the crypto market. Even with the recent downturn and the tailwinds the industry is facing, bulls keep being positive.
2025-11-18 05:47 5mo ago
2025-11-18 00:23 5mo ago
Bitcoin Price Crashes Below $90K—Is the 2025 Crypto Bear Market Here? cryptonews
BTC
Bitcoin’s sudden drop below $90,000 has sent shockwaves across the crypto market, fueling fears that the long-awaited bull cycle may finally be losing steam. Social media is buzzing with panic, analysts are split, and traders are scrambling to decode whether this sharp correction is simply a healthy cooldown—or the first major sign of a deeper crypto bear market. With liquidity thinning and macro uncertainty rising, the big question remains: Is this the start of something bigger, or just another shakeout before the next leg higher for the Bitcoin (BTC) price rally?

What’s Driving the Bitcoin Sell-Off?Bitcoin’s fall below $90,000 came as a result of several overlapping market triggers. Fresh data from the past few hours points to a combination of whale activity, derivatives pressure, thinning liquidity, and renewed macro caution—all accelerating BTC’s slide.

Profit-Taking After Sideways ConsolidationBTC spent nearly a week struggling to break above the $93,000–$94,000 resistance area. As soon as the price began slipping below $91,000, short-term traders who accumulated during the previous range started locking in profits. Although harder to quantify, ETF outflow patterns earlier this week indicate fading speculative appetite, adding to the momentum behind early selling.

Liquidity Thinning During Off-Peak HoursThe initial drop occurred during a low-liquidity window across U.S. and Asian trading hours, leaving exchanges more vulnerable to large sell orders. Real-time market depth showed weaker bids across major platforms, allowing even moderate selling to push BTC lower. This effect became more pronounced once automated orders and stop-losses began firing.

Derivatives Liquidations Accelerating Downside PressureLeveraged traders played a major role in the speed of the decline. In the past 24 hours alone, Bitcoin recorded $116.8 million in liquidations, with $95.3 million coming from long positions—highlighting how aggressively bullish futures traders were caught offside. Across all crypto assets, liquidations totalled nearly $370 million, creating a cascading effect that intensified the sell-off.

Macro Risk-Off Mood Weighing on SentimentAhead of crucial U.S. economic data, markets turned cautious, pushing investors toward safer assets. A stronger dollar, rising Treasury yields, and weakening equity momentum contributed to a broader risk-off tone. Bitcoin, despite being viewed as a long-term hedge, often mirrors risk-asset behavior during short-term uncertainty—and this week was no exception.

Whale Movements Fueling Market AnxietyLarge on-chain transfers added to the pressure. In the past few hours, a whale moved 3,300 BTC (≈ $297 million) from Bitfinex to an unknown wallet—a transfer size that typically signals high-value repositioning or preemptive hedging. Such large moves often unsettle traders, especially when they coincide with a broader market decline.

Retail Fear Triggered by the Break Below $90,000When Bitcoin slipped under the psychological $90K mark, retail sentiment flipped sharply. Social platforms saw a spike in negative keywords such as “BTC crash,” “sell Bitcoin,” and “bear market incoming.” Combined with liquidation-driven volatility, this fear-led exit by smaller traders added to the downward pressure.

Are We in a Crypto Bear Market?Bitcoin’s decline under $90,000 has reignited a fierce debate among analysts—but no clear verdict has emerged. On one side, voices like CryptoQuant CEO Ki Young Ju warn of a potential deeper drop if BTC fails to reclaim critical long-term moving averages. The appearance of a “death cross” and increasing long-position liquidations raise red flags.

On the flip side, some market observers argue this is merely a healthy mid-cycle correction, not the end of the bull run. They point to robust on-chain accumulation and historical pullback patterns as evidence that a sustained bear market may not be underway. Ultimately, whether this is a fleeting consolidation or a lasting downtrend will depend on key support holds and renewed institutional momentum.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.
2025-11-18 05:47 5mo ago
2025-11-18 00:25 5mo ago
Ripple price slips to $2.15 with room for further downside cryptonews
XRP
Can the Ripple price hold near $2.15, or is the market preparing for another move toward lower levels?

Summary

XRP is trading near $2.15 after a steep slide from its July peak, with weak buying interest across key levels.
Technical indicators show soft momentum, and analysts warn that losing $2.12 could open a path toward $2.10 and $2.05.
ETF launches are drawing attention, but price action remains muted as many holders sit on losses and selling pressure stays elevated.

Ripple is under pressure. XRP is trading near $2.15 after a 5% decline in the past 24 hours and is now about 40% below its July peak of $3.65.

Analysts say the market structure has weakened as Bitcoin (BTC) has slipped below $90,000, mainly because a large share of Ripple (XRP) holders are sitting on losses, increasing the risk of further selling if sentiment deteriorates.

Tony Sycamore of IG Australia notes that the drop caught both long-term holders and new buyers off guard. Many had positioned for continued upside, while late entrants bought near the top out of fear of missing out.

Technical indicators are not offering support. XRP is below $2.20 and under the 100-hour simple moving average. A downward trend line near $2.22 continues to cap any attempt at recovery. The token also remains below the 23.6% Fibonacci retracement level, showing weak buying interest at current prices.

XRP price chart | Source: crypto.news
Momentum signals point the same way. The hourly MACD is firmly negative, and the RSI has slipped below 50. Analysts say that failure to clear $2.22 keeps the $2.12 support exposed. If that level breaks, a move toward $2.10 and $2.05 becomes likely.

This weakness appears even as investor interest in XRP ETFs is rising. The recent ETF launch attracted more attention than any other US ETF debut of 2025. Four additional spot XRP ETFs from Franklin Templeton, Bitwise, 21Shares, and CoinShares are set to follow.

JPMorgan estimates that these ETFs could draw $4–8 billion in their first year, adding institutional capital that XRP has not consistently received. A previous XRPR ETF launch in the US drove an 18% price gain ahead of trading and quickly gathered $150 million in assets.

Market behaviour today, however, has been muted. Prices continue to fall despite positive ETF activity, which shows that technical weakness and cautious sentiment are dominating near-term movement.

Some analysts argue that XRP may be stabilizing above $2, but they also point out that any meaningful reversal would require a move above $2.62. CoinGlass data shows heavy supply zones between $2.34 and $2.67, signalling that attempts to recover are likely to meet resistance.

Sycamore notes that a broader recovery requires a break back above $2.70 after clearing several intermediate hurdles including $2.22, $2.28, $2.32, and $2.40.

If buyers fail to protect $2.10, the decline could speed up, opening the path to $2.05 and potentially $1.88, which is about 12% lower than current levels. The next two trading sessions will show whether incoming ETF-driven demand can counter the ongoing pressure created by retail holders still underwater.
2025-11-18 05:47 5mo ago
2025-11-18 00:29 5mo ago
VanEck Chief Says Investors Should Hold Both Bitcoin and Gold for Portfolio Balance cryptonews
BTC
During a recent appearance on Schwab Network, VanEck chief executive officer Jan van Eck has opined that investors should hold both Bitcoin and gold in order to be able to maintain a proper portfolio balance.  

The prominent entrepreneur thinks that these assets are actually very similar since they have a limited supply. 

"I think they're very similar in terms of their role in people's portfolios. It's sort of a store of assets, and they both have limited supply."

HOT Stories

"A crypto hippie"He has recalled that VanEck was actually the first ETF sponsor to file for a Bitcoin ETF in 2017, which is before it was popular, when it was a $3,000 token. 

"So maybe I'm a crypto hippie. But I think yes, we suggest that people own both just to have that as a role in their portfolios because it helps during different market cycles," he noted. 

What VanEck dislikes about Bitcoin At the same time, the VanEck boss says that he does not like the fact that Bitcoin is now highly correlated with the Nasdaq index. He argues that people do not want another risk asset in their portfolios. 

"I would say the one negative thing I don't like about Bitcoin, having followed it for a long time, is that it's become very highly correlated with the NASDAQ and people don't want, they don't need just another risk-on asset in their portfolio just for the sake of having it," he said.

Bitcoin used to be a "wonderful" diversifier, the VanEck boss notes. "I'm just kind of hoping things go through cycles, Diane. I'm just hoping the cycle changes a little bit and that correlation comes down," he said. 
2025-11-18 05:47 5mo ago
2025-11-18 00:35 5mo ago
Bitcoin Slides Below $90K as Market Fear Deepens Amid Liquidity Crunches cryptonews
BTC
Bitcoin plunged under the $90,000 mark on Tuesday in Hong Kong trading, extending a sharp multi-week selloff that has erased all of its gains for 2025 and pushed sentiment to its lowest levels since the 2022 bear market. The move down to $89,420 on Coinbase — the lowest price since February — comes just weeks after the cryptocurrency hit a record high above $126,000, underscoring how quickly market momentum has shifted.

The decline accelerated after Bitcoin failed to reclaim the key $93,700 support level over the weekend. Breaking below its 200-day moving average triggered a bearish “death cross” between the 50-day and 200-day trendlines, a technical signal that often aligns with extended drawdowns when liquidity is waning. Current conditions reflect that pattern, with market depth thinning out and demand from major spot Bitcoin ETFs stalling.

U.S. spot Bitcoin ETFs, which saw over $25 billion in inflows earlier this year, have recorded nearly two weeks of flat activity. Investors appear cautious amid fears that the Trump administration’s tariff agenda could fuel inflation and push the Federal Reserve to delay anticipated interest-rate cuts. Corporate buyers that aggressively accumulated BTC in early 2025 have also pulled back.

Retail sentiment has deteriorated sharply. The crypto Fear & Greed Index fell to 11, signaling “extreme fear,” while Bitcoin’s social dominance surged as traders shift attention away from altcoins toward BTC during what may be a capitulation phase. Analysts caution that if Bitcoin cannot reclaim the $93,000 level soon, it could slide into a liquidity pocket between $86,000 and $88,000.

Still, some market observers believe the severe sentiment shock could set the stage for a short-term relief rally if ETF flows stabilize and macro data turns less hawkish. Investor Dan Tapiero noted that some capital may be rotating into stablecoins and tokenized real-world assets, but maintains that Bitcoin’s long-term fundamentals and institutional adoption remain strong, calling the current volatility “just noise.”

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>
2025-11-18 05:47 5mo ago
2025-11-18 00:40 5mo ago
Dubai Court Freezes $456M Linked to TrueUSD Reserves as Recovery Efforts Intensify cryptonews
TUSD
A Dubai court has frozen roughly $456 million connected to TrueUSD’s reserves, marking a major development in an ongoing dispute involving stablecoin operator Techteryx, fiduciary custodian First Digital Trust (FDT), and the Aria Group. The funds became illiquid in 2023 after being redirected into complex investment structures tied to Aria, a move that led to a significant shortfall and forced an emergency bailout from Justin Sun to keep TrueUSD operational.

According to FDT CEO Vincent Chok, the company fully supports Techteryx’s legal push to recover the missing funds. In an email to CoinDesk, Chok noted that the court has ordered Aria to disclose details about the assets in question—an important step toward determining where the funds are held and whether they can be reclaimed. Although FDT was not a party to the Dubai case, the situation is closely linked to its former role as fiduciary custodian of TrueUSD’s reserves.

Techteryx had previously directed FDT to invest reserves into the Aria Commodity Finance Fund in the Cayman Islands. However, filings in Hong Kong later alleged that approximately $456 million was instead transferred to Aria Commodities DMCC, a distinct Dubai-based Aria entity. There, the assets reportedly became locked in illiquid trade-finance positions, prompting the Dubai Digital Economy Court to freeze the funds while the investigation continues.

Chok emphasized that FDT acted strictly as an intermediary and executed every transaction under Techteryx’s explicit instructions. Meanwhile, the firm is also pursuing a defamation lawsuit against Justin Sun, who alleged in April that FDT was “effectively insolvent,” briefly causing its own stablecoin, FDUSD, to lose its peg. Chok stated that there are currently no public updates regarding the case.

This unfolding situation continues to draw attention across the crypto industry, as investors watch closely for outcomes that could impact stablecoin transparency, custodial responsibilities, and regulatory compliance moving forward.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>
2025-11-18 05:47 5mo ago
2025-11-18 00:40 5mo ago
Bitcoin Sinks Below $90,000: Popular Analyst Says This Is When BTC Will Reach Market Bottom cryptonews
BTC
An influential cryptocurrency analyst predicted Monday when Bitcoin (CRYPTO: BTC) is likely to hit its bottom, even as the leading cryptocurrency crashed below $90,000.

Another Year Of Bearish Pain?Ali Martinez made a bold prediction for X, saying that the apex cryptocurrency would bottom in October 2026. They based their projection on the historical trend of Bitcoin bear markets lasting “364 days.”

Martinez cited examples from the 2017-18 market, where BTC bottomed in December 2018 after peaking in December 2017, and the 2021-22 market, when the leading cryptocurrency hit its lowest point in November 2022 after peaking a year ago.

“Assuming Bitcoin reached a market top on Oct. 6 at $126,200, the next market bottom could be in October 2026, presenting an ideal buying opportunity,” the analyst stated.

See Also: Nayib Bukele Goes ‘Hooah’ As El Salvador Buys $98 Million Worth Of Bitcoin In A Day Amid Crypto Meltdown

Crypto Market Retreats From HighsMartinez’s prediction comes at a time when leading cryptocurrencies, including Bitcoin, are experiencing sharp declines. Late Monday, Bitcoin sank below $90,000, marking its lowest point in nearly seven months.

Capital markets commentator The Kobeissi Letter highlighted that since Bitcoin’s all-time high, the cryptocurrency market has erased $1.2 trillion in market capitalization, amounting to 28% of its total value.

“It’s safe to say that crypto just experienced its ‘2025 bear market,'” The Kobeissi Letter remarked.

The Peaks And The TroughsWhile the likes of Martinez are already discussing market bottoms, popular Wall Street Strategist Tom Lee didn’t support the idea that the market has peaked, instead suggesting that the "next" cryptocurrency cycle top is 12–36 months away.

Meanwhile, the market’s “Extreme Fear” sentiment intensified,  according to the Crypto Fear & Greed Index, hitting levels last seen in the last week of February.

Price Action: At the time of writing, BTC was exchanging hands at $89,836.72, down 5.55% in the last 24 hours, according to data from Benzinga Pro.

Read Next: 

The Real Reason Behind Bitcoin’s Drop From $126,000 To $95,000 In 6 Weeks
Disclaimer: This content was partially produced with the help of Benzinga Neuro and was reviewed and published by Benzinga editors.

Photo by Frame Stock Footage via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
2025-11-18 05:47 5mo ago
2025-11-18 00:44 5mo ago
Mt. Gox moves $956 million worth of bitcoin to unmarked wallet address: Arkham cryptonews
BTC
While the motive behind the bitcoin transfer remains unclear, such transactions have typically preceded repayments from the defunct exchange.
2025-11-18 05:47 5mo ago
2025-11-18 00:46 5mo ago
Fidelity and Canary Launch New Solana ETFs as SOL Price Faces Volatility cryptonews
SOL
The crypto market is set for a major shift as two new spot Solana ETFs begin trading today, expanding investor options even as SOL’s price faces sharp swings. Bloomberg ETF analysts confirmed that the Fidelity Solana ETF (FSOL) and the Canary Marinade Solana ETF (SOLC) will officially launch on Tuesday, bringing the total number of spot Solana ETFs in the U.S. market to five.

Fidelity’s FSOL becomes effective following an 8-A filing and will trade on NYSE Arca under the ticker FSOL. With a management fee of 0.25%, Fidelity enters the Solana ETF arena as one of the most influential asset managers to back SOL directly. Bloomberg’s Eric Balchunas highlighted that Fidelity is the largest asset manager participating in Solana ETFs so far, noting that BlackRock continues to limit its ETF lineup to Bitcoin and Ethereum. Bitwise’s BSOL has already surpassed $450 million in assets under management, signaling strong institutional interest.

Canary Capital, in collaboration with Marinade Finance, is also debuting the Canary Marinade Solana ETF (SOLC) on Nasdaq. The fund, which integrates Marinade as its staking partner, will carry a management fee of 0.50%. Bloomberg analyst James Seyffart confirmed the launch, emphasizing growing competition as new Solana ETFs enter the market.

Despite consistent inflows—nearly $400 million across all Solana ETFs—SOL’s price has been under pressure. The token dropped more than 20% over the past week and fell 9% today, currently trading around $134.35. Still, Solana rebounded more than 3% from its daily low, supported by a 60% surge in trading volume. Derivatives data from CoinGlass shows rising bullish sentiment, with total futures open interest climbing to $7.43 billion.

As institutional participation increases with these ETF launches, market watchers anticipate renewed momentum for Solana despite short-term volatility.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>
2025-11-18 04:48 5mo ago
2025-11-17 21:48 5mo ago
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Synopsys, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SNPS stocknewsapi
SNPS
November 17, 2025 9:48 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 17, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Synopsys, Inc. (NASDAQ: SNPS) between December 4, 2024 and September 9, 2025, both dates inclusive (the "Class Period"), of the important December 30, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Synopsys securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Synopsys class action, go to https://rosenlegal.com/submit-form/?case_id=44981 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 30, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) the extent to which Synopsys' increased focus on artificial intelligence customers, which require additional customization, was deteriorating the economics of its Design IP business; (2) that, as a result, "certain road map and resource decisions" were unlikely to "yield their intended results,"; (3) that the foregoing had a material negative impact on financial results; and (4) as a result of the foregoing, defendants' positive statements about Synopsys' business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Synopsys class action, go to https://rosenlegal.com/submit-form/?case_id=44981 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274852
2025-11-18 04:48 5mo ago
2025-11-17 21:50 5mo ago
Cathie Wood Is Selling SoFi Stock. Should You? stocknewsapi
SOFI
The digital bank stock is up 81% this year.

Cathie Wood is known for her trend-setting tech sector investments, and she has become one of the most-watched investors, since followers watch to see what she'll spot before the market does.

She is firmly committed to tech disruptors, and her company's exchange-traded funds (ETF) sport curated groups of innovative tech stocks.

Unsurprisingly, SoFi Technologies (SOFI 2.80%) holds a significant position in the Ark Fintech Innovation ETF (ARKF 2.92%), which focuses on financial technology disruption. The digital bank continues to electrify the market and launch new, innovative financial products, demonstrating incredible growth and resilience.

SoFi accounts for 3.8% of the fintech ETF, but Ark was selling shares last week. Is this a signal as to how Wood feels about SoFi? And should you follow her lead?

Image source: SoFi.

Why SoFi stock has exploded
SoFi was one of the earlier digital banks to land on the scene. These days, probably every bank has an online portal, but SoFi is completely online and has no branches. While that might not appeal to some customers who want the security of having a bank they can walk into, it's attracting millions of users who prefer robust tech investments over costly real estate. This is a mostly younger clientele, and it's SoFi's sweet spot. The bank targets students and young professionals, people who are used to doing everything with their phone and want that experience for managing their finances.

Management has concentrated its efforts on developing a full platform to meet the needs of this population. Its strategy is to onboard these younger users and grow with them along their financial journeys. Since these users are often just getting started, that creates a reliable long-term revenue opportunity as a user needs more services, like graduating from a student loan to a savings account and a credit card, and then perhaps to an investment account and so on. Marketing costs have been one of SoFi's major expenses, but as it scales and cross-sells new products, it's making more money without adding customer acquisition costs.

Right now, it continues to break records each quarter for the amount of new customers it adds to the platform. Even when this eventually tapers off, it will still have high growth opportunities as these customers age and increase engagement with the platform.

More market share to capture, more disruptions coming
In the meantime, it's adding customers at a fast pace, including 905,000 new users in the third quarter, a 34% increase year over year, and one of the ways it's attracting new business is by adding innovative services.

It recently brought back cryptocurrency trading, for example, which it had to cut out when it got a bank charter due to regulatory measures. Those measures have changed, and SoFi recently relaunched the product. It is the only nationally chartered bank where customers can buy, sell, and trade certain cryptocurrencies straight from their SoFi Money app, using funds in their accounts instead of needing to open a separate account for cryptocurrency trading purposes.

It had also already announced that it's going to offer global remittances, a type of international wire transfer, straight on the app using the blockchain network. Management has committed to launching other blockchain-based products to make money management easy, quick, and cost-effective.

Today's Change

(

-2.80

%) $

-0.78

Current Price

$

27.04

Right up Cathie Wood's alley
Wood is usually a big fan of these kinds of products, so it's surprising that she was selling SoFi stock last week.

There could be various reasons why she was selling. One is just to free up cash, since she was buying other stocks for the fintech ETF, including DoorDash and Bitmine Immersion Technologies.

Another is that as SoFi stock rises, it's become more expensive. She hasn't sold that much of SoFi, and I wouldn't look at this trade as an indication of lost confidence in SoFi or its opportunities. It's likely to be a bit of both the reasons mentioned. Considering how much SoFi stock has rocketed higher this year, it's a good candidate for selling off a small portion if she needs the money for another opportunity.

Don't forget, she runs an investment company, so her job is to maximize gains, and her style is to take risks. The average investor may be better off finding a great stock like SoFi and holding on to it for many years as it continues to thrive.
2025-11-18 04:48 5mo ago
2025-11-17 21:54 5mo ago
SINA DEADLINE TOMORROW: ROSEN, A TOP RANKED LAW FIRM, Encourages Sina Corporation Investors to Secure Counsel Before Important November 18 Deadline in Securities Class Action - SINA stocknewsapi
SINA
November 17, 2025 9:54 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 17, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds sellers of ordinary shares, including those that sold into the Merger of Sina Corporation (NASDAQ: SINA) between October 13, 2020 and March 22, 2021, both dates inclusive (the "Class Period"), of the important November 18, 2025 lead plaintiff deadline in the securities class action.

SO WHAT: If you sold Sina ordinary shares, including those that sold into the Merger, during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Sina class action, go to https://rosenlegal.com/submit-form/?case_id=45219 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 18, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants' created a fraudulent scheme to depress the value of Sina ordinary shares to avoid paying a fair price to Sina's shareholders in connection with the Merger. Defendants executed this scheme by misrepresenting and/or omitting material information within and from Sina's proxy materials in connection with the Merger that were necessary for shareholders to make an informed decision concerning whether to vote in favor of the Merger. Specifically, defendants failed to disclose that: (1) defendants concealed the true value of Sina's investment in TuSimple at the time of the Merger; (2) in turn, the offer of $43.30 per ordinary share as consideration for the Merger substantially shortchanged the true value of Sina ordinary shares; and (3) as a result, defendants' statements about Sina's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

To join the Sina class action, go to https://rosenlegal.com/submit-form/?case_id=45219 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274847
2025-11-18 04:48 5mo ago
2025-11-17 21:56 5mo ago
Oil and Natural Gas Technical Analysis – Critical Breakout and Breakdown Zones to Watch stocknewsapi
BNO DBO GUSH IEO OIH OIL PXJ UCO USO XOP
On the other hand, demand expectations improved slightly as the U.S. government reopened, restoring activity across key sectors. Travel, holiday spending, and workforce mobility are likely to lift near-term consumption. However, structural oversupply remains the dominant force in the market. Until inventories tighten or supply risks intensify, oil prices may struggle to move higher despite occasional support from geopolitical events.

WTI Crude Oil (CL) Technical Analysis
WTI Oil Daily Chart – Consolidation
The daily chart for WTI crude oil (CL) indicates that the price is consolidating below the key $60 level, exhibiting negative price action. A break above $62.50 would signal further upside potential toward the $66 area. However, as long as the price remains below the 200-day SMA, the overall trend in the oil market remains bearish. Additionally, the RSI remains below the midpoint, signaling that sellers continue to drive weakness and negative momentum in the oil market.
2025-11-18 04:48 5mo ago
2025-11-17 22:03 5mo ago
Mayfair Gold Q3 2025 Financial and Operating Results stocknewsapi
MFGCF
, /PRNewswire/ - Mayfair Gold Corp. ("Mayfair", or the "Company") (TSXV: MFG) (OTCQX: MFGCF) is pleased to report its operating and financial results for the quarter ended September 30, 2025. Mayfair is focused on the exploration and development of its 100% controlled Fenn-Gib gold project located in the Timmins region of Northeast Ontario ("Fenn-Gib" or the "Project"). The full version of the financial statements and accompanying management's discussion and analysis can be viewed on the Company's website at www.mayfairgold.ca or on SEDAR+ at www.sedarplus.com. Unless otherwise stated, all amounts are presented in Canadian dollars.

Mayfair's Chief Executive Officer Nicholas Campbell commented,

"Dear Stakeholders, 

I am pleased to provide an update on our progress at Mayfair Gold and the Fenn-Gib Gold project in Northern Ontario.  In Q3 2025, Mayfair completed a $40 million LIFE Offering which secured substantial funding to support the Mayfair Gold and advance the Fenn-Gib gold project through permitting, detailed engineering and community engagement. The company continued to advance work on the Pre-Feasibility Study ("PFS") for a 4,800 tpd open pit operation targeting the high-grade near surface zone of mineralization at Fenn-Gib. 

The Company commenced a confidence drilling program in October 2025, which will give Mayfair more data to better define waste to ore boundaries and improve confidence in the grade profile for the mine over the first several years of production. Results of the drill program are expected to be available in Q1 2026. Mayfair continues to focus on derisking the Fenn-Gib gold project. The PFS remains on track to be completed in Q4 2025 with formal Provincial permitting activities expected to commence at the start of 2026. 

With a strong balance sheet, an established team to advance the Fenn-Gib Project, execute the construction of the mine and with the upcoming PFS to illustrate the potential economics of 4,800 tpd open pit targeted the high-grade zone at Fenn-Gib, Mayfair Gold is very excited about the prospects for the Company as we unlock the value of Fenn-Gib and work to advance Mayfair Gold into a new Canadian Gold producer."

Corporate Highlights During the Quarter

On September 4, 2025, the Company held the Annual General and Special Meeting of Shareholders. Mayfair shareholders approved the re-election of Darren McLean, Carson Block, Zach Allwright, Sean Pi and Christine Hsieh; the re-appointment of Davidson & Company LLP as auditors of the Company; and the approval of a new 10% rolling Omnibus Incentive Plan to replace the existing stock option plan.
On September 16, 2025, the Company closed the LIFE offering resulting in the issuance of 24,244,000 common shares at a price of $1.65 per common share for gross proceeds of $40,002,600. The Company intends to use the net proceeds from the offering for metallurgical and detailed engineering at its Fenn‐Gib gold project in Timmins, Ontario, and for working capital and general corporate purposes.
Subsequent to September 30, 2025, the Company filed its Annual Information Form for the year ended December 31, 2024, on SEDAR

Exploration Highlight

Subsequent to September 30, 2025, the Company filed a technical reported prepared in accordance with National Instrument 43-101 Standards of Disclosure for Mineral Projects for the Fenn-Gib Gold Project. The effective date of this updated mineral resource estimate is September 3, 2024.

Selected Financial Data

The following selected financial data is summarized from the Company's financial statements and related notes thereto for the three and nine months ended September 30, 2025 and 2024.

Three months ended

September 30,

Nine months ended

September 30,

2025

2024

2025

2024

$

$

$

$

Loss and comprehensive loss

(2,241,177)

(1,434,837)

(6,169,868)

(10,456,025)

Loss per share – basic and diluted

(0.02)

(0.01)

(0.06)

(0.10)

September 30,

2025

December 31,
2024

$

$

Cash and cash equivalents and short-term investments

41,814,681

9,534,129

Total assets

56,748,042

24,489,347

Total current liabilities

1,182,371

749,934

Total liabilities

1,182,371

749,934

Total shareholders' equity

55,565,671

23,739,413

About Mayfair Gold

Mayfair Gold is a well-funded Canadian gold development company focused on advancing the 100%-owned Fenn-Gib gold project in the Timmins region of Northern Ontario. The Fenn-Gib gold deposit hosts an Indicated Resource of 181.3 Mt grading 0.74 g/t Au for 4.3 million contained gold. Mayfair is focused on advancing Fenn-Gib through the Ontario Provincial permitting process to transition Mayfair into a new Canadian gold producer in the current gold cycle.

The scientific and technical content of this news release was reviewed, verified, and approved by Drew Anwyll, P.Eng., M.Eng, Chief Operating Officer of the Company, and a Qualified Person as defined by Canadian Securities Administrators' National Instrument 43-101 - Standards of Disclosure for Mineral Projects ("NI 43-101").

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.

Cautionary Notes to U.S. Investors Concerning Resource Estimates

This news release has been prepared in accordance with the requirements of the securities laws in effect in Canada, which differ from the requirements of the U.S. securities laws. In particular, and without limiting the generality of the foregoing, the terms "inferred mineral resources," "indicated mineral resources" and "mineral resources" used or referenced in this presentation are Canadian mineral disclosure terms as defined in accordance with NI 43-101 under the guidelines set out in the 2014 Canadian Institute of Mining, Metallurgy and Petroleum Standards for Mineral Resources and Mineral Reserves, Definitions and Guidelines, May 2014 (the "CIM Standards"). The CIM Standards differ from the mineral property disclosure requirements of the U.S. Securities and Exchange Commission (the "SEC") in Regulation S-K Subpart 1300 (the "SEC Modernization Rules") under the U.S. Securities Act of 1933, as amended (the "Securities Act"). As a foreign private issuer that is eligible to file reports with the SEC pursuant to the multijurisdictional disclosure system, the Company is not required to provide disclosure on its mineral properties under the SEC Modernization Rules and will continue to provide disclosure under NI 43-101 and the CIM Standards. Accordingly, the Company's disclosure of mineralization and other technical information may differ significantly from the information that would be disclosed had the Company prepared the information under the standards adopted under the SEC Modernization Rules.

Forward Looking Information

This news release contains forward-looking information which reflects management's expectations regarding the Company's growth, results of operations, performance and business prospects and opportunities. Forward-looking statements in this news release include, but are not limited to, statements the design, development and execution of the Fenn-Gib Gold Project, the timing for completion of the PFS, the advancement of the Fenn-Gib Gold Project to operation and the timing thereof, advancing Fenn-Gib to production and cash flow expected to help fund potential future growth opportunities, and including the potential to permit and develop a larger operation at Fenn-Gib. Forward-looking information is based on various reasonable assumptions including, without limitation, the expectations and beliefs of management; the assumed long-term price of gold; that the Company can access financing, appropriate equipment and sufficient labour; and that the political environment where the Company operates will continue to support the development and operation of mining projects. Should underlying assumptions prove incorrect, or one or more of the risks and uncertainties described below materialize, actual results may vary materially from those described in forward-looking statements.

 Forward-looking information is subject to a variety of risks and uncertainties which could cause actual events or results to differ from those reflected in the forward-looking information, including, without limitation, risks and uncertainties relating to foreign currency fluctuations; risks inherent in mining including environmental hazards, industrial accidents, unusual or unexpected geological formations, ground control problems and flooding; delays or the inability to obtain necessary governmental permits or financing; risks associated with the estimation of mineral resources and reserves and the geology, grade and continuity of mineral deposits; the possibility that future exploration, development or mining results will not be consistent with the Company's expectations; the potential for and effects of labor disputes or other unanticipated difficulties with or shortages of labor; failure of plant, equipment or processes to operate as anticipated; actual ore mined varying from estimates of grade, tonnage, dilution and metallurgical and other characteristics; the inherent uncertainty of production and cost estimates and the potential for unexpected costs and expenses, gold price fluctuations; uncertain political and economic environments; and changes in laws or policies.

The Company undertakes no obligation to publicly update or review the forward-looking statements whether as a result of new information, future events or otherwise, other than as required under applicable securities laws. The forward-looking statements reflect management's beliefs, opinions and projections as of the date of this news release.

SOURCE Mayfair Gold Corp.
2025-11-18 04:48 5mo ago
2025-11-17 22:05 5mo ago
Omdia: Southeast Asia smartphone shipments slip 1% in 3Q25 as vendors face mounting cost pressures stocknewsapi
TTGT
LONDON--(BUSINESS WIRE)-- #Consumer--Latest research from Omdia shows that the Southeast Asia's smartphone market declined 1% in 3Q25, with shipments totaling 25.6 million units - the third consecutive quarter of year-on-year contraction. Samsung led the region with 4.6 million units and an 18% share, driven by its premium-leaning portfolio in higher-ASP markets such as Thailand, Vietnam and Malaysia. This helped offset competitors' gains in more price-sensitive markets like Indonesia and the Philippines.
2025-11-18 04:48 5mo ago
2025-11-17 22:12 5mo ago
Bitcoin price drops below $90,500, its lowest level since April cryptonews
BTC
Long-term holders and ETF outflows drive rare sell-off, stirring market fear amid shifting accumulation patterns.

Key Takeaways

Bitcoin's price dropped below $90,500, breaking key support levels.
Heavy selling by long-term holders and large ETF outflows are driving the decline.

Bitcoin dropped below $90,500 for the first time since April amid heavy selling pressure from long-term holders and ETF outflows that weakened market momentum.

Traders are showing signs of capitulation as fear, uncertainty, and doubt spread on social media during the ongoing price corrections.

The decline comes despite Bitcoin successfully retesting previous resistance levels turned support during recent pullbacks, suggesting the sell-off pressure has intensified beyond technical support zones.

Heavy selling from long-term holders and ETF outflows are contributing to the weakened market conditions, marking a shift from the typical accumulation patterns seen from these investor groups.

Disclaimer
2025-11-18 04:48 5mo ago
2025-11-17 22:12 5mo ago
Bitcoin Faces Historic November as ETF Outflows and Fear Spike Across the Crypto Market cryptonews
BTC
Bitcoin is on the brink of registering one of the worst months in its market history, with ETF outflows accelerating, quarterly returns weakening and market sentiment plunging into extreme fear. The sudden reversal comes after the leading cryptocurrency slipped below the $100,000 mark, losing a key psychological level that once attracted strong institutional buying.
2025-11-18 04:48 5mo ago
2025-11-17 22:07 5mo ago
PRGO CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Perrigo Company plc stocknewsapi
PRGO
LOS ANGELES--(BUSINESS WIRE)--PRGO CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Perrigo Company plc.
2025-11-18 04:48 5mo ago
2025-11-17 22:47 5mo ago
El Salvador discloses largest single-day BTC purchase of $100 million as bitcoin dips lower cryptonews
BTC
However, it is unclear whether El Salvador actually bought 1,090 BTC, as its deal with the IMF required the country to cease new purchases.